form8k.htm

0000920527-11-000090.txt : 20111027 0000920527-11-000090.hdr.sgml : 20111027 20111027083252 ACCESSION NUMBER: 0000920527-11-000090 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20111027 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20111027 DATE AS OF CHANGE: 20111027 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PSS WORLD MEDICAL INC CENTRAL INDEX KEY: 0000920527 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-MEDICAL, DENTAL & HOSPITAL EQUIPMENT & SUPPLIES [5047] IRS NUMBER: 592280364 STATE OF INCORPORATION: FL FISCAL YEAR END: 0327 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-23832 FILM NUMBER: 111160440 BUSINESS ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 BUSINESS PHONE: 9043323000 MAIL ADDRESS: STREET 1: 4345 SOUTHPOINT BLVD STREET 2: STE 250 CITY: JACKSONVILLE STATE: FL ZIP: 32216 FORMER COMPANY: FORMER CONFORMED NAME: PHYSICIAN SALES & SERVICE INC /FL/ DATE OF NAME CHANGE: 19940318 8-K 1 form8k.htm FORM 8-K form8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2011

PSS WORLD MEDICAL, INC.

(Exact name of Registrant as specified in its charter)

Commission File Number: 0-23832

Florida	59-2280364
(State or other jurisdiction	(IRS Employer
of incorporation or organization)	Identification Number)

4345 Southpoint Blvd.
Jacksonville, Florida	32216
(Address of principal executive offices)	(Zip code)


Registrant’s telephone number, including area code	(904) 332-3000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Disclosure of Results of Operations and Financial Condition.

On October 27, 2011, PSS World Medical, Inc. (the “Company”) issued a press release in which the Company announced its financial results for the three and six months ended September 30, 2011. This press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. In connection with the press release, the Company has also made available certain supplemental financial information (the “Financial Supplement”) for the three and six months ended September 30, 2011, which may be found on the Company’s website at www.pssd.com. This Financial Supplement is attached as Exhibit 99.2 to this report and is incorporated herein by reference.

The Financial Supplement contains financial measures that are not in accordance with accounting principles generally accepted in the United States of America ("GAAP"). The Company has provided reconciliations within the Financial Supplement of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company provides non-GAAP financial measures to supplement its consolidated financial statements presented in accordance with GAAP. These non-GAAP financial measures are intended to supplement the user's overall understanding of the Company's current financial performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company's core operating results or business performance. However, these non-GAAP financial measures are not intended to supersede or replace the Company's GAAP results.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number	Description
99.1	Press Release dated October 27, 2011 with respect to the Registrant’s financial results for the three and six months ended September 30, 2011.
99.2	Financial Supplement for the three and six months ended September 30, 2011.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PSS WORLD MEDICAL, INC.

Date: October 27, 2011	By:	/s/	David M. Bronson
		Name	David M. Bronson
		Title	Executive Vice President and Chief Financial Officer

EXHIBIT INDEX

99.1	Press Release dated October 27, 2011.

99.2	Financial Supplement for the three and six months ended September 30, 2011.

EX-99.1 2 earningsrelease.htm PRESS RELEASE 10/27/2011 earningsrelease.htm

N E W S R E L E A S E

Contact:

PSS World Medical

Investor Relations

904-332-3287

PSS WORLD MEDICAL REPORTS RESULTS FOR

FISCAL YEAR 2012 SECOND QUARTER

Second Quarter Highlights:

·	Consolidated net sales growth of 5.2%

o	Physician Business net sales growth of 9.7%

o	Elder Care Business net sales decline of 5.2%

·	Consolidated earnings per diluted share of $0.37

·	Consolidated cash flow from operations of $22.6 million

·	Consolidated return on committed capital of 38.7%

Jacksonville, Florida (October 27, 2011) – PSS World Medical, Inc. (NasdaqGS: PSSI) announced today its results for the fiscal year 2012 second quarter ended September 30, 2011.

President and Chief Executive Officer, Gary A. Corless commented, “Our company’s Purpose is to strengthen the clinical success and financial health of caregivers by solving their biggest problems. This quarter, we focused and quantified that Purpose by defining and launching a new Mission statement to directly address our customers’ greatest challenge, their financial health. We have committed to improving their overall financial performance by 20%.”

“The financial viability of our nation’s caregivers is critical to the care they deliver and the future of our healthcare system,” added Corless. “This bold and unique Mission we are undertaking is an opportunity to leverage the largest, most highly trained sales force with the broadest offering of products and services to effect significant and positive change for caregivers, as well as profitable growth for our shareholders. This, combined with the successful momentum of our core business strategies, we believe will drive the achievement of our financial goals for the year, including our fiscal 2012 goal for earnings per share of $1.46 - $1.50.”

Net sales for the three months ended September 30, 2011, were $521.8 million, an increase of 5.2%, compared with net sales of $496.2 million for the three months ended October 1, 2010. Net sales for the three months ended September 30, 2011, for the Physician Business increased by 9.7% and decreased by 5.2% for the Elder Care Business. Income from operations for the three months ended September 30, 2011, was $36.3 million compared with income from operations for the three months ended October 1, 2010, of $35.4 million. Net income for the three months ended September 30, 2011, was $20.0 million, or $0.37 per diluted share, compared with net income for the three months ended October 1, 2010, of $19.6 million, or $0.35 per diluted share. Each of the three-month periods during the second quarter of fiscal years 2012 and 2011 included 63 sales days.

-MORE-

PSSI Reports Results For Fiscal 2012 Second Quarter

Page 2

October 27, 2011

Net sales for the six months ended September 30, 2011, were $1,035.4 million, an increase of 6.2%, compared with net sales of $975.0 million for the six months ended October 1, 2010. Net sales for the six months ended September 30, 2011, for the Physician Business increased by 10.8% and decreased by 4.0% for the Elder Care Business. Income from operations for the six months ended September 30, 2011, was $62.8 million compared with income from operations for the six months ended October 1, 2010, of $60.7 million. Net income for the six months ended September 30, 2011, increased by 2.7% to $34.2 million, or $0.61 earnings per diluted share, compared with net income for the six months ended October 1, 2010, of $33.3 million, or $0.59 earnings per diluted share.

David M. Bronson, Executive Vice President and Chief Financial Officer, commented, “The Company continued to execute well on our core strategies in the second quarter of fiscal 2012, offsetting very sluggish healthcare system utilization with share gains, operating improvements, and accretive deployment of capital. Second quarter operating margin, earnings per share, and return on committed capital were at or near historic highs, despite revenue growth challenges brought on by ongoing economic headwinds.

“Taking a stand on the side of the nation’s caregivers and committing to improve their financial performance is the right thing to do,” Bronson continued. “It will also afford us the opportunity to showcase and exploit our unique competitive advantages, which we believe will reward our shareholders with profitable growth.”

A listen-only simulcast as well as a 90-day online replay of PSS World Medical’s fiscal year 2012 second quarter conference call can be found in the Investor Relations/Financial Information sections of the Company’s website, www.pssworldmedical.com, under the heading “Events and Presentations,” on October 27, 2011, beginning at 8:30 a.m. Eastern time.

The Company has today filed with the SEC a Form 8-K that includes a copy of this press release and its related Fiscal Year 2012 Second Quarter Financial Workbook, which contains GAAP and non-GAAP financial measures, and is available on the Company’s website, www.pssworldmedical.com. Additional financial information pertaining to PSS World Medical financial results may be found by visiting the Investor Relations section of the Company’s website, www.pssworldmedical.com, under the heading “Events and Presentations.” If you should need assistance accessing the information, please call Investor Relations at 904-332-3287.

PSS World Medical, Inc. is a national distributor of medical products to physicians and extended care providers through its two business units. Since its inception in 1983, PSS has become a leader in the two market segments that it serves with a focused market approach to customer services, a consultative sales force, strategic acquisitions, strong arrangements with product manufacturers and a unique culture of performance.

Certain statements in this release are “forward-looking statements” made pursuant to the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements are identified by the use of words such as “expect,” “may,” “will,” “should,” “believe,” “plan,” “anticipate,” and “estimate” among others. These statements involve a number of risks and uncertainties, many of which are outside the control of the Company. Actual results may differ materially from those identified in the forward-looking statements. Among the factors that could cause results to differ materially are the following: fluctuating demand for our products and services; national and global economic and political conditions; our and our customers’ ability to obtain financing; the introduction of new products and services offered by us and our competitors; uncertainty of the impact of recently enacted healthcare laws; consolidation of healthcare providers; proper functioning of our data processing and information technology systems; our ability to successfully execute our global sourcing strategy; pricing pressures on large national and regional accounts and GPOs; customer credit quality and our ability to collect our accounts receivable, particularly in states with significant budget deficits; our ability to successfully execute our mergers and acquisitions strategy; our ability to compete with other medical supply companies and direct manufacturers; multi-tiered cost structures where certain institutions can obtain more favorable prices for medical products than us; our ability to maintain relationships with our suppliers and customers; our ability to retain sales reps and key management; our ability to execute our growth strategy; increased operating costs, including fuel and other commodity prices; risks involved in maintaining a large amount of inventory; our indebtedness may limit our ability to obtain additional financing or react to market conditions; we face litigation and product liability exposure; weather-related events such as hurricanes may disrupt our and our customers’ business; we may be deemed to infringe other persons intellectual property; our and our customers’ businesses are subject to numerous federal, state and foreign laws and regulations that could impact our and their financial condition and results of operations; general business, competitive and economic factors and conditions; and other factors described from time to time in the Company’s reports filed with the Securities and Exchange Commission. PSS World Medical, Inc. assumes no obligation to update the information in this release except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.

-MORE-

PSSI Reports Results For Fiscal 2012 Second Quarter

Page 3

October 27, 2011

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statement of Operations

(in millions, except per share and share data)

	For the Three Months Ended						For the Six Months Ended
	September 30,			October 1,			September 30,			October 1,
	2011			2010			2011			2010
Net sales	$	521.8		$	496.2		$	1,035.4		$	975.0
Cost of goods sold		354.7			339.1			707.5			670.0
Gross profit		167.1			157.1			327.9			305.0
General and administrative expenses		94.5			87.4			193.5			177.4
Selling expenses		36.3			34.3			71.6			66.9
Income from operations		36.3			35.4			62.8			60.7

Other (expense) income:
Interest expense		(4.7	)		(4.2	)		(9.2	)		(8.4	)
Interest income		0.1			-			0.1			0.1
Other income		0.4			0.5			1.0			1.0
Other expense		(4.2	)		(3.7	)		(8.1	)		(7.3	)

Income before provision for income taxes		32.1			31.7			54.7			53.4
Provision for income taxes		12.0			12.0			20.4			19.9
Net income		20.1			19.7			34.3			33.5
Net income attributable to noncontrolling interest		0.1			0.1			0.1			0.2
Net income attributable to PSS World Medical, Inc.	$	20.0		$	19.6		$	34.2		$	33.3

Earnings per common share attributable to PSS World Medical, Inc.:
Basic	$	0.38		$	0.36		$	0.64		$	0.60
Diluted	$	0.37		$	0.35		$	0.61		$	0.59

Weighted average shares (in thousands):
Basic		52,309			54,985			53,237			55,539
Diluted		53,956			55,887			55,672			56,905

-MORE-

PSSI Reports Results For Fiscal 2012 Second Quarter

Page 4

October 27, 2011

PSS World Medical, Inc.

Unaudited Condensed Consolidated Balance Sheets

(in millions except share data)

	September 30,			April 1,
	2011			2011

ASSETS
Current Assets:
Cash and cash equivalents		$	34.8		$	29.3
Accounts receivable, net			244.6			247.2
Inventories			229.4			213.2
Prepaid expenses and other			50.7			54.9
Total current assets			559.5			544.6

Property and equipment, net			100.2			102.4

Other Assets:
Goodwill			174.0			167.1
Intangibles, net			40.3			41.9
Other			90.8			95.7
Total assets		$	964.8		$	951.7

LIABILITIES AND EQUITY
Current Liabilities:
Accounts payable		$	151.5		$	128.1
Accrued expenses			41.8			37.2
Revolving line of credit and current portion of long-term debt			50.4			0.8
Other			22.4			33.1
Total current liabilities			266.1			199.2
Long-term debt, excluding current portion			200.2			195.7
Other noncurrent liabilities			93.4			110.2
Total liabilities			559.7			505.1

Equity:
PSS World Medical, Inc. shareholders' equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized,
no shares issued and outstanding			-			-
Common stock, $0.01 par value; 150,000,000 shares authorized,
52,704,672 and 55,465,600 shares issued and outstanding
as of September 30, 2011 and April 1, 2011, respectively			0.5			0.5
Additional paid-in capital			47.1			122.9
Retained earnings			353.8			319.6
Total PSS World Medical, Inc. shareholders' equity			401.4			443.0
Noncontrolling interest			3.7			3.6
Total equity			405.1			446.6
Total liabilities and equity		$	964.8		$	951.7

-MORE-

PSSI Reports Results For Fiscal 2012 Second Quarter

Page 5

October 27, 2011

PSS WORLD MEDICAL, INC.

Unaudited Condensed Consolidated Statements of Cash Flows

(in millions)

	Three Months Ended						Six Months Ended
	September 30,			October 1,			September 30,			October 1,
	2011			2010			2011			2010
Cash Flows From Operating Activities:
Net income	$	20.1		$	19.6		$	34.3		$	33.5
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation		6.6			6.1			13.1			12.0
Amortization of debt discount and issuance costs		2.5			2.3			5.0			4.6
Amortization of intangible assets		2.1			1.5			4.2			2.9
Noncash compensation expense		1.6			2.6			3.7			5.3
Benefit for deferred income taxes		(3.1	)		(2.4	)		(2.4	)		(2.8	)
Provision for doubtful accounts		0.2			0.6			0.7			0.8
Provision for deferred compensation		0.2			0.4			0.5			0.8
Changes in operating assets and liabilities, net of effects
from business combinations:
Accounts receivable, net		(6.8	)		(10.1	)		3.4			(3.8	)
Inventories		(6.3	)		(3.2	)		(15.7	)		(1.7	)
Prepaid expenses and other current assets		1.9			(12.7	)		(5.2	)		(13.8	)
Other assets		(3.4	)		(2.2	)		(5.6	)		(4.1	)
Accounts payable		5.9			11.6			23.3			12.5
Accrued expenses and other liabilities		1.1			(2.5	)		(1.8	)		(7.7	)
Net cash provided by operating activities		22.6			11.6			57.5			38.5

Cash Flows From Investing Activities:
Capital expenditures		(6.3	)		(3.6	)		(10.9	)		(8.0	)
Payments for business acquisitions, net of cash acquired		(10.1	)		(6.4	)		(10.3	)		(6.5	)
Payment for investment in variable interest entity, net of cash		-			-			-			(3.3	)
Other		-			(0.3	)		(0.1	)		(0.5	)
Net cash used in investing activities		(16.4	)		(10.3	)		(21.3	)		(18.3	)

Cash Flows From Financing Activities:
Proceeds from borrowings on the revolving line of credit		101.4			17.2			131.6			17.2
Repayments on the revolving line of credit		(71.9	)		(17.2	)		(81.6	)		(17.2	)
Purchase and retirement of common stock		(23.1	)		(38.7	)		(80.9	)		(51.7	)
Excess tax benefits from share-based compensation arrangements		0.1			0.6			1.3			1.1
Payment of contingent consideration on business acquisition		-			-			(1.0	)		-
Payments under capital lease obligations		(0.2	)		(0.2	)		(0.4	)		(0.5	)
Proceeds from exercise of stock options		-			0.6			0.3			0.9
Other		-			0.2			-			0.1
Net cash provided by (used in) financing activities		6.3			(37.5	)		(30.7	)		(50.1	)

Net increase (decrease) in cash and cash equivalents		12.5			(36.2	)		5.5			(29.9	)
Cash and cash equivalents, beginning of period		22.3			59.1			29.3			52.8
Cash and cash equivalents, end of period	$	34.8		$	22.9		$	34.8		$	22.9

-END-

EX-99.2 3 financialsupplement.htm FINANCIAL SUPPLEMENT 10/27/2011 financialsupplement.htm

Financial Supplement

For the Second Quarter of Fiscal Year 2012 ending September 30, 2011

PSS World Medical, Inc.

As of September 30, 2011

Current Fiscal Year Consolidated Income Statement

(in thousands, except per share data)

	2012
	Q1			Q2			YTD

Net sales	$	513,682		$	521,756		$	1,035,438
Cost of goods sold		352,925			354,653			707,578
Gross profit		160,757			167,103			327,860
General & administrative expenses		98,998			94,511			193,510
Selling expenses		35,247			36,325			71,573
Income from operations		26,512			36,266			62,778
Interest expense		(4,538	)		(4,668	)		(9,207	)
Interest income		74			53			127
Other income		532			437			968
Income from operations before income taxes		22,579			32,088			54,666
Provision for income taxes		8,434			11,962			20,396
Net income		14,145			20,125			34,270
Net income attributable to noncontrolling interest		(44	)		94			50
Net income attributable to PSS World Medical, Inc.	$	14,189		$	20,031		$	34,221

Earnings per common share attributable to PSS World Medical, Inc.:
Basic	$	0.26		$	0.38		$	0.64
Diluted	$	0.25		$	0.37		$	0.61

Weighted average common shares outstanding:
WASO - Basic		54,166			52,309			53,237
WASO - Diluted		57,388			53,956			55,672

Net sales by segment:
Physician Business	$	366,308		$	376,870		$	743,179
Elder Care Business		146,926			144,237			291,163
Corporate Shared Services		448			648			1,096
	$	513,682		$	521,756		$	1,035,438

Selling days:		64			63			127

Net sales per selling day:
Physician Business	$	5,724		$	5,982		$	5,852
Elder Care Business		2,296			2,289			2,293
Corporate Shared Services		7			10			9
	$	8,026		$	8,282		$	8,153

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Consolidated Income Statement Trend

(in thousands, except per share data)

	Fiscal Year 2009															Fiscal Year 2010															Fiscal Year 2011
	Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total

Net sales	$	472,215		$	491,603		$	519,145		$	469,728		$	1,952,691		$	493,554		$	561,976		$	502,764		$	496,877		$	2,055,171		$	478,856		$	496,188		$	510,087		$	549,658		$	2,034,789
Cost of goods sold		333,283			344,347			364,282			328,868			1,370,781			347,581			389,404			348,064			342,427			1,427,476			331,010			339,063			352,192			376,753			1,399,018
Gross profit		138,931			147,255			154,863			140,860			581,910			145,974			172,571			154,700			154,449			627,695			147,846			157,125			157,895			172,905			635,771
General and administrative expenses		89,634			90,689			89,426			82,728			352,478			91,638			97,208			89,439			92,586			370,871			89,986			87,399			88,860			98,505			364,749
Selling expenses		31,266			32,161			33,721			31,356			128,505			32,687			36,728			33,249			33,178			135,842			32,610			34,298			34,330			36,229			137,466
Income from operations		18,031			24,405			31,715			26,776			100,927			21,649			38,635			32,012			28,685			120,981			25,250			35,429			34,706			38,171			133,556
Interest expense		(3,203	)		(5,300	)		(7,409	)		(6,247	)		(22,159	)		(4,261	)		(4,532	)		(4,214	)		(4,288	)		(17,295	)		(4,137	)		(4,226	)		(4,243	)		(4,515	)		(17,121	)
Interest income		122			842			1,034			305			2,304			134			95			117			30			376			66			46			33			139			284
Other income		608			520			877			638			2,643			3,995			452			741			879			6,068			544			412			852			698			2,506
Income from ops before income taxes		15,559			20,467			26,218			21,472			83,716			21,517			34,650			28,657			25,306			110,130			21,723			31,661			31,348			34,493			119,225
Provision for income taxes		6,187			8,104			10,230			7,709			32,229			8,213			12,964			10,736			8,854			40,768			7,892			12,016			11,757			12,895			44,560
Net income		9,372			12,363			15,989			13,763			51,486			13,304			21,686			17,921			16,452			69,363			13,831			19,644			19,592			21,598			74,664
Net income attributable to noncontrolling interest		-			-			-			-			-			-			-			-			-			-			78			87			42			(28	)		179
Net income attributable PSS World Medical, Inc.	$	9,372		$	12,363		$	15,989		$	13,763		$	51,486		$	13,304		$	21,686		$	17,921		$	16,452		$	69,363		$	13,753		$	19,557		$	19,549		$	21,626		$	74,485

Earnings per common share attributable to PSS World Medical, Inc.:
Basic	$	0.15		$	0.21		$	0.27		$	0.23		$	0.86		$	0.23		$	0.37		$	0.31		$	0.29		$	1.20		$	0.25		$	0.36		$	0.36		$	0.40		$	1.36
Diluted	$	0.15		$	0.20		$	0.27		$	0.23		$	0.85		$	0.23		$	0.37		$	0.30		$	0.28		$	1.18		$	0.24		$	0.35		$	0.35		$	0.38		$	1.32

Weighted average common shares outstanding:
Basic		61,003			59,941			59,481			59,307			59,937			58,380			58,566			58,522			56,627			58,029			56,093			54,985			54,357			54,548			54,996
Diluted		61,723			60,921			60,322			59,801			60,696			58,859			59,390			59,390			58,115			58,943			57,924			55,887			55,567			56,789			56,546

Net Sales by Segment:
Physician Business	$	331,386		$	341,761		$	357,269		$	326,966		$	1,357,382		$	342,292		$	398,531		$	352,961		$	344,039		$	1,437,823		$	327,403		$	343,403		$	357,298		$	396,908		$	1,425,012
Elder Care Business		140,406			149,485			161,874			142,743			594,509			150,381			162,970			149,400			152,187			614,937			151,202			152,173			152,263			152,111			607,750
Corporate Shared Services		423			356			2			19			800			882			475			403			651			2,411			251			612			526			639			2,028
	$	472,215		$	491,603		$	519,145		$	469,728		$	1,952,691		$	493,554		$	561,976		$	502,764		$	496,877		$	2,055,171		$	478,856		$	496,188		$	510,087		$	549,658		$	2,034,789

Billing Days:		64			63			66			60			253			64			68			61			65			258			64			63			61			65			253

Net Sales Per Billing Day:
Physician Business	$	5,178		$	5,425		$	5,413		$	5,449		$	5,365		$	5,348		$	5,861		$	5,786		$	5,293		$	5,573		$	5,116		$	5,451		$	5,857		$	6,106		$	5,632
Elder Care Business		2,194			2,373			2,453			2,379			2,350			2,350			2,397			2,449			2,341			2,383			2,363			2,415			2,496			2,340			2,402
Corporate Shared Services		7			6			-			-			3			14			7			7			10			9			4			10			9			10			8
	$	7,378		$	7,803		$	7,866		$	7,829		$	7,718		$	7,712		$	8,264		$	8,242		$	7,644		$	7,966		$	7,482		$	7,876		$	8,362		$	8,456		$	8,043

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Our Brands - Net Sales

(in thousands)

	Fiscal Year
	2012						2011
	Q1		Q2		YTD		Q1		Q2		Q3		Q4		YTD

Consolidated Our Brand Sales	$	87,734	$	90,703	$	178,437	$	80,555	$	82,152	$	84,551	$	86,978	$	334,237






	Fiscal Year
	2007		2008		2009		2010		2011

Consolidated Our Brand Sales	$	185,844	$	234,810	$	281,536	$	323,602	$	334,237

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Segment Information

(in thousands)

	Three Months Ended						Six Months Ended
	September 30,			October 1,			September 30,			October 1,
	2011			2010			2011			2010

NET SALES:
Physician Business	$	376,870		$	343,403		$	743,179		$	670,806
Elder Care Business		144,237			152,173			291,163			303,376
Corporate Shared Services		648			612			1,096			863
Total net sales	$	521,756		$	496,188		$	1,035,438		$	975,045

SELLING DAYS:		63			63			127			127

NET SALES PER SELLING DAY:
Physician Business	$	5,982		$	5,451		$	5,852		$	5,282
Elder Care Business		2,289			2,415			2,293			2,389
Corporate Shared Services		10			10			9			7
Total net sales per selling day	$	8,282		$	7,876		$	8,153		$	7,678

INCOME FROM OPERATIONS:
Physician Business	$	38,933		$	37,130		$	69,180		$	64,753
Elder Care Business		7,331			8,759			14,618			16,688
Corporate Shared Services		(9,998	)		(10,461	)		(21,020	)		(20,762	)
Total income from operations	$	36,266		$	35,429		$	62,778		$	60,679

DEPRECIATION:
Physician Business	$	2,750		$	2,283		$	5,406		$	4,461
Elder Care Business		1,294			1,251			2,592			2,468
Corporate Shared Services		2,597			2,566			5,086			5,113
Total depreciation	$	6,641		$	6,100		$	13,084		$	12,041

AMORTIZATION OF INTANGIBLE
AND OTHER ASSETS:
Physician Business	$	1,339		$	559		$	2,677		$	1,111
Elder Care Business		595			775			1,192			1,517
Corporate Shared Services		175			167			349			316
Total amortization of intangible and other assets	$	2,108		$	1,501		$	4,217		$	2,944

PROVISION FOR DOUBTFUL ACCOUNTS:
Physician Business	$	492		$	646		$	725		$	878
Elder Care Business		(269	)		(26	)		(71	)		(64	)
Total provision for doubtful accounts	$	223		$	620		$	654		$	814

INTEREST EXPENSE:
Total interest expense	$	4,668		$	4,226		$	9,207		$	8,363

INTEREST INCOME:
Physician Business	$	4		$	-		$	10		$	-
Elder Care Business		38			25			89			51
Corporate Shared Services		11			21			28			61
Total interest and investment income	$	53		$	46		$	127		$	112

PROVISION (BENEFIT) FOR INCOME TAXES:
Physician Business	$	14,275		$	13,632		$	25,069		$	23,676
Elder Care Business		2,021			2,567			4,004			4,780
Corporate Shared Services		(4,334	)		(4,182	)		(8,677	)		(8,548	)
Total provision for income taxes	$	11,962		$	12,016		$	20,396		$	19,908

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Current Fiscal Year Consolidated Balance Sheet

(in thousands)

	As of
	July 1,		September 30,
ASSETS	2011		2011

Cash	$	22,291	$	34,848
Accounts receivable, net		236,967		244,615
Inventory, net		222,660		229,400
Prepaid expenses		8,355		7,170
Other current assets		51,582		43,432
Total current assets		541,854		559,465

Property and equipment, net		100,620		100,225
Goodwill		167,386		173,958
Intangibles, net		40,012		40,330
Other long-term assets		96,829		90,803

Total assets	$	946,700	$	964,780

LIABILITIES & EQUITY

Accounts payable	$	145,495	$	151,478
Accrued expenses		41,556		41,787
Current portion of long term debt		574		380
Revolving line of credit		20,500		50,000
Other current liabilities		20,761		22,418
Total current liabilities		228,886		266,063

Long-term debt		197,904		200,185
Other non-current liabilities		113,407		93,478

Total liabilities		540,196		559,727

Total PSS World Medical, Inc. shareholders' equity		402,948		401,403
Noncontrolling interest		3,556		3,650
Total equity		406,504		405,053

Total liabilities and equity	$	946,700	$	964,780

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Consolidated Balance Sheet Trend

(in thousands)

	Fiscal Year 2009								Fiscal Year 2010								Fiscal Year 2011
ASSETS	Jun-08		Sep-08		Dec-08		Mar-09		Jun-09		Sep-09		Dec-09		Mar-10		Jun-10		Sep-10		Dec-10		Mar-11

Cash	$	29,840	$	226,055	$	214,709	$	82,031	$	129,631	$	130,089	$	114,056	$	52,751	$	59,081	$	22,949	$	36,912	$	29,348
Investment in available for sale securities		-		-		-		10,592		-		-		-		-		-		-		-		-
Accounts receivable, net		227,661		240,806		232,894		230,361		230,391		257,968		233,602		227,888		222,544		232,014		239,082		247,229
Inventory, net		192,707		199,337		239,940		207,593		196,160		212,813		230,725		218,911		217,500		220,846		240,211		213,211
Deferred tax assets		6,805		-		-		8,059		8,250		5,602		11,986		15,629		15,101		19,514		17,789		20,533
Other current assets		26,157		22,163		23,229		23,819		24,385		30,854		33,980		26,485		27,753		40,979		32,693		34,285
Total current assets		483,170		688,361		710,772		562,456		588,817		637,326		624,349		541,664		541,979		536,301		566,687		544,606

Property and equipment, net		92,803		96,849		97,113		101,205		103,552		105,499		106,956		105,220		103,737		101,269		101,958		102,401
Goodwill		112,320		112,392		112,717		112,768		114,255		115,280		120,828		121,772		124,281		128,745		131,364		167,094
Intangibles, net		25,738		24,345		23,102		22,958		22,442		21,604		25,289		24,548		25,242		26,440		30,657		41,879
Investment in available for sale securities		14,231		16,725		15,333		-		-		-		-		-		-		-		-		-
Other long-term assets		67,598		83,055		70,549		59,238		65,065		73,819		77,748		78,862		77,488		84,933		91,881		95,693

Total assets	$	795,860	$	1,021,726	$	1,029,587	$	858,624	$	894,131	$	953,528	$	955,170	$	872,066	$	872,727	$	877,688	$	922,547	$	951,672

	Fiscal Year 2009								Fiscal Year 2010								Fiscal Year 2011
LIABILITIES & EQUITY	Jun-08		Sep-08		Dec-08		Mar-09		Jun-09		Sep-09		Dec-09		Mar-10		Jun-10		Sep-10		Dec-10		Mar-11

Accounts payable	$	128,656	$	149,674	$	155,133	$	127,300	$	133,781	$	156,966	$	137,676	$	123,970	$	125,155	$	137,431	$	149,698	$	128,057
Accrued expenses		38,055		50,816		43,170		52,718		46,196		43,248		48,051		50,253		37,830		33,804		40,075		37,175
Current portion of long-term debt		196,116		198,022		199,606		50,937		50,953		50,970		56,321		881		1,190		1,297		1,133		761
Deferred tax liabilities, current		-		6,619		4,492		-		-		-		-		-		-		-		-		-
Other current liabilities		8,102		8,723		9,160		7,956		12,882		13,653		13,122		10,954		25,576		26,574		24,346		33,211
Total current liabilities		370,928		413,855		411,560		238,910		243,812		264,837		255,169		186,058		189,751		199,107		215,252		199,204

Long-term debt		706		177,650		179,395		180,965		182,654		184,530		186,153		187,941		189,746		191,667		193,645		195,662
Other long-term liabilities		68,975		64,763		56,503		60,719		70,323		79,896		86,674		90,053		77,748		86,420		92,940		110,281

Total liabilities		440,610		656,268		647,459		480,594		496,789		529,263		527,996		464,052		457,245		477,193		501,837		505,146

Total PSS World Medical, Inc. shareholders' equity		355,250		365,458		382,127		378,030		397,342		424,265		427,174		408,014		412,344		397,270		417,082		442,926
Noncontrolling interest		-		-		-		-		-		-		-		-		3,138		3,225		3,628		3,600
Total equity		355,250		365,458		382,127		378,030		397,342		424,265		427,174		408,014		415,482		400,495		420,710		446,526

Total liabilities & equity	$	795,860	$	1,021,726	$	1,029,587	$	858,624	$	894,131	$	953,528	$	955,170	$	872,066	$	872,727	$	877,688	$	922,547	$	951,672

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Current Fiscal Year Unaudited Operating Highlights

(in millions)

	Three Months Ended						Six Months Ended
	September 30,			October 1,			September 30,			October 1,
	2011			2010			2011			2010

Net sales:
Physician Business	$	376.9		$	343.4		$	743.2		$	670.8
Elder Care Business		144.2			152.2			291.2			303.4
Corporate Shared Services		0.6			0.6			1.1			0.9
Total net sales	$	521.8		$	496.2		$	1,035.4		$	975.0

Income from operations:
Physician Business	$	38.9		$	37.1		$	69.2		$	64.8
Elder Care Business		7.3			8.8			14.6			16.7
Corporate Shared Services		(10.0	)		(10.5	)		(21.0	)		(20.8	)
Total income from operations	$	36.3		$	35.4		$	62.8		$	60.7

EBITDA(a)	$	45.5		$	43.4		$	81.0		$	76.6

Income from operations, as a percentage of net sales		7.0	%		7.1	%		6.1	%		6.2	%

Consolidated Return on Committed Capital ("ROCC")(b)		38.7	%		36.7	%		33.5	%		31.8	%

Selling Days		63			63			127			127

Net Sales Per Selling Day (in thousands):
Physician Business	$	5,982		$	5,451		$	5,852		$	5,282
Elder Care Business		2,289			2,415			2,293			2,389
Corporate Shared Services		10			10			9			7
Total Net Sales Per Selling Day	$	8,282		$	7,876		$	8,153		$	7,678

Net Sales Per Selling Day Growth Rate:
Physician Business		9.7	%					10.8	%
Elder Care Business		(5.2	%)					(4.0	%)
Total Net Sales Per Selling Day Growth Rate		5.2	%					6.2	%

	Annualized
	September 30,			October 1,
	2011			2010
DSO(c)
Physician Business		39.1			40.1
Elder Care Business		46.4			48.7
DOH(d)
Physician Business		53.2			57.6
Elder Care Business		64.7			59.9
DIP(e)
Physician Business		37.6			39.9
Elder Care Business		23.5			23.2
Cash Conversion Days(f)
Physician Business		54.7			57.8
Elder Care Business		87.6			85.4

	As of
	September 30,			October 1,
	2011			2010
Operational working capital(g)	$	322.5		$	315.4

Net debt:
Convertible senior notes	$	200.2		$	191.3
Bank debt		50.0			0.5
Other debt		0.3			1.2
Less: Cash and cash equivalents		(34.8	)		(22.9	)
Net debt	$	215.7		$	170.1

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

September 30, 2011

Non-GAAP Reconciliations

(in millions)

Consolidated net sales impact from Physician Dispensing Acquisitions

	Three Months Ended					Six Months Ended
	September 30,		October 1,		Percent	September 30,		October 1,		Percent
	2011		2010		Change	2011		2010		Change

Consolidated Net Sales	$	521.8	$	496.2	5.2%	$	1,035.4	$	975.0	6.2%
Less: Net Sales from Physician Dispensing		19.4		-			39.0		-
Net Sales less the impact of Physician Dispensing	$	502.3	$	496.2	1.2%	$	996.4	$	975.0	2.2%

Physician Business net sales impact from Physician Dispensing Acquisitions

	Three Months Ended					Six Months Ended
	September 30,		October 01,		Percent	September 30,		October 01,		Percent
	2011		2010		Change	2011		2010		Change

Physician Business Net Sales	$	376.9	$	343.4	9.7%	$	743.2	$	670.8	10.8%
Less: Net Sales from Physician Dispensing		19.4		-			39.0		-
Net Sales less the impact of Physician Dispensing	$	357.4	$	343.4	4.1%	$	704.1	$	670.8	5.0%

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Selling Days Calendar FY11-FY13

FY2011		FY2012		FY2013
Closing	Selling	Closing	Selling	Closing	Selling
Date	Days	Date	Days	Date	Days	Notes
30-Apr	20	29-Apr	20	27-Apr	20	A
28-May	20	27-May	20	25-May	20	A
2-Jul	24	1-Jul	24	29-Jun	24	B
Q1	64		64		64
30-Jul	19	29-Jul	19	27-Jul	19	A
27-Aug	20	26-Aug	20	31-Aug	25	A
1-Oct	24	30-Sep	24	28-Sep	19	B
Q2	63		63		63
29-Oct	20	28-Oct	20	26-Oct	20	A
26-Nov	18	25-Nov	18	30-Nov	23	A
31-Dec	23	30-Dec	24	28-Dec	19	B
Q3	61		62		62
28-Jan	20	27-Jan	19	25-Jan	19	A
25-Feb	20	24-Feb	20	22-Feb	20	A
1-Apr	25	30-Mar	25	29-Mar	25	B
Q4	65		64		64
Total	253		253		253


A	Closing date is the last Friday of the month (for non-quarter end months).

B	"Selling Days" defines closing date as the Friday closest to month end
	based on business days only (for quarter end months only).

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

September 30, 2011

EBITDA Calculation

Current Fiscal Year

(in thousands)

	2012
	Q1			Q2

Net Income	$	14,145		$	20,125
Plus:
Interest expense		4,538			4,668
Provision for income taxes		8,434			11,962
Depreciation		6,443			6,641
Amortization of intangible assets		2,109			2,108

Less:
Interest income		(74	)		(53	)

EBITDA	$	35,595		$	45,452

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

September 30, 2011

EBITDA Calculation

(in thousands)

	Fiscal Year 2009															Fiscal Year 2010															Fiscal Year 2011
	Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total

Net income	$	9,372		$	12,363		$	15,989		$	13,763		$	51,486		$	13,304		$	21,686		$	17,921		$	16,452		$	69,363		$	13,831		$	19,644		$	19,592		$	21,598		$	74,664

Plus:
Interest expense		3,203			5,300			7,409			6,247			22,159			4,261			4,532			4,214			4,288			17,295			4,137			4,226			4,243			4,515			17,121
Provision for income taxes		6,187			8,104			10,230			7,709			32,229			8,213			12,964			10,736			8,854			40,768			7,892			12,016			11,757			12,895			44,560
Depreciation		4,830			4,912			5,116			5,144			20,002			5,245			5,256			5,558			5,881			21,940			5,942			6,100			6,260			6,763			25,065
Amortization of intangible assets		1,344			1,553			1,264			1,328			5,489			1,252			1,190			1,235			1,444			5,121			1,444			1,501			1,584			1,850			6,378

Less:
Interest and investment income		(122	)		(842	)		(1,034	)		(305	)		(2,304	)		(134	)		(95	)		(117	)		(30	)		(376	)		(66	)		(46	)		(33	)		(139	)		(284	)

EBITDA	$	24,813		$	31,390		$	38,973		$	33,886		$	129,062		$	32,140		$	45,533		$	39,547		$	36,890		$	154,110		$	33,179		$	43,441		$	43,402		$	47,483		$	167,504

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Consolidated Return on Committed Capital (ROCC)

Current Fiscal Year

(in thousands)

	2012
	Q1			Q2
Consolidated Return on Committed Capital:
Quarterly Average Committed Capital (1)	$	400,211		$	401,138

Committed Capital - Current Quarter		395,794			406,482
Committed Capital - Previous Quarter		404,628			395,794

Return on Committed Capital - Quarterly (2)		29.1	%		38.7	%

Return:
Net income		14,145			20,125

Add:
Provision for income taxes		8,434			11,962
Interest expense		4,538			4,668
Amortization		2,109			2,108
Interest and investment income		(74	)		(53	)
	$	29,152		$	38,811

Committed Capital:
Total assets	$	946,700		$	964,780
Less assets excluded:
Cash		(22,291	)		(34,848	)
Goodwill and intangibles, net		(207,397	)		(214,288	)

Total liabilities		(540,196	)		(559,727	)
Plus liabilities excluded:
Current debt		21,074			50,380
Long-term debt		197,904			200,185
	$	395,794		$	406,482

(1)	Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.

(2)	Return on Committed Capital equals Return divided by Committed Capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

As of September 30, 2011

Consolidated Return on Committed Capital (ROCC) Trend

(in thousands)

	Fiscal Year 2009															Fiscal Year 2010															Fiscal Year 2011
	Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total			Q1			Q2			Q3			Q4			Total
Consolidated Return on Committed Capital:
Quarterly Average Committed Capital(1)	$	390,439		$	381,257		$	394,469		$	401,387					$	378,397		$	378,706		$	401,134		$	403,620					$	397,789		$	406,570		$	415,941		$	410,592
Annual Average Committed Capital(2)													$	394,438														$	394,969														$	401,196

Committed Capital - Current Quarter		384,175			378,339			410,600			392,174						364,619			392,792			409,475			397,765						397,814			415,325			416,556			404,628			404,628
Committed Capital - Previous Quarter		396,702			384,175			378,339			410,600						392,174			364,619			392,792			409,475						397,765			397,814			415,325			416,556			416,556
Committed Capital - Current Year End														392,174															397,765															397,765
Committed Capital - Previous Year End														396,702															392,174															397,765

Return on Committed Capital - Quarterly(3)		20.5	%		27.8	%		34.3	%		28.6	%					28.4	%		42.5	%		33.9	%		30.7	%					27.4	%		36.7	%		35.7	%		39.7	%
Return on Committed Capital - Annual														27.6	%														33.5	%														35.5	%

Return:
Net Income	$	9,372		$	12,363		$	15,989		$	13,763		$	51,486		$	13,304		$	21,686		$	17,921		$	16,452		$	69,363		$	13,831		$	19,644		$	19,592		$	21,598		$	74,664

Add:
Provision for income taxes		6,187			8,104			10,230			7,709			32,229			8,213			12,964			10,736			8,854			40,768			7,892			12,016			11,757			12,895			44,560
Interest expense		3,203			5,300			7,409			6,247			22,159			4,261			4,532			4,214			4,288			17,295			4,137			4,226			4,243			4,515			17,121
Amortization		1,344			1,553			1,264			1,328			5,489			1,252			1,190			1,235			1,444			5,121			1,444			1,501			1,584			1,850			6,378
Interest and investment income		(122	)		(842	)		(1,034	)		(305	)		(2,304	)		(134	)		(95	)		(117	)		(30	)		(376	)		(66	)		(46	)		(33	)		(139	)		(284	)

	$	19,983		$	26,478		$	33,856		$	28,742		$	109,059		$	26,895		$	40,277		$	33,989		$	31,009		$	132,170		$	27,238		$	37,341		$	37,141		$	40,719		$	142,440

Committed Capital:
Total assets	$	795,860		$	1,021,726		$	1,029,586		$	858,624		$	858,624		$	894,131		$	953,528		$	955,170		$	872,065		$	872,065		$	872,727		$	877,688		$	922,547		$	951,672		$	951,672
Less assets excluded:
Cash		(29,840	)		(226,055	)		(214,709	)		(82,031	)		(82,031	)		(129,631	)		(130,089	)		(114,056	)		(52,751	)		(52,751	)		(59,081	)		(22,949	)		(36,912	)		(29,348	)		(29,348	)
Goodwill and intangibles, net		(138,058	)		(136,736	)		(135,820	)		(135,726	)		(135,726	)		(136,696	)		(136,884	)		(146,117	)		(146,320	)		(146,320	)		(149,523	)		(155,185	)		(162,020	)		(208,973	)		(208,973	)

Total liabilities		(440,610	)		(656,268	)		(647,459	)		(480,594	)		(480,594	)		(496,792	)		(529,263	)		(527,996	)		(464,052	)		(464,052	)		(457,246	)		(477,193	)		(501,837	)		(505,146	)		(505,146	)
Plus liabilities excluded:
Current debt		196,116			198,022			199,606			50,937			50,937			50,953			50,970			56,321			881			881			1,190			1,297			1,133			761			761
Long-term debt		706			177,650			179,395			180,965			180,965			182,654			184,530			186,153			187,941			187,941			189,746			191,667			193,645			195,662			195,662
	$	384,175		$	378,339		$	410,600		$	392,174		$	392,174		$	364,619		$	392,792		$	409,475		$	397,765		$	397,765		$	397,814		$	415,325		$	416,556		$	404,628		$	404,628

(1)	Quarterly Average Committed Capital equals the sum of the committed capital of the most recent two quarters, divided by two.

(2)	Annual Average Committed Capital equals the sum of the committed capital of the most recent two year ends, divided by two.

(3)	Return on Committed Capital equals return divided by committed capital. Quarterly calculations are annualized.

Numbers may not foot due to rounding differences

PSS World Medical, Inc.

Footnotes

(a)

EBITDA represents net income plus provision for income taxes, interest expense, depreciation, and amortization of intangible assets, less interest and investment income. Management reviews EBITDA when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes EBITDA is an important measure of liquidity.

(b)

ROCC equals return divided by average committed capital. Return is annualized for quarterly and year to date calculations. Management reviews ROCC when evaluating and comparing the performance of each operating segment on a quarterly basis. Management believes ROCC is an important measure of profitability and return.

(c)

DSO is average accounts receivable divided by average daily net sales. Average accounts receivable is the sum of accounts receivable, net of the allowance for doubtful accounts, at the beginning and end of the most recent four quarters divided by five. Average daily net sales are net sales for the most recent four quarters divided by 360.

(d)	DOH is average inventory divided by average daily cost of goods sold (“COGS”). Average inventory is the sum of inventory at the beginning and end of the most recent four quarters divided by five. Average daily COGS is quarterly COGS for the most recent four quarters divided by 360.

(e)	DIP is average accounts payable divided by average daily COGS. Average accounts payable is the sum of accounts payable at the beginning and end of the most recent four quarters divided by five.

(f)	Cash Conversion Days is the sum of DSO and DOH less DIP.

(g)	Operational working capital equals accounts receivable, net, plus inventory minus accounts payable.

GRAPHIC 4 psswmlogo_expdel.jpg PSS WORLD MEDICAL LOGO begin 644 psswmlogo_expdel.jpg M_]C_X``02D9)1@`!`0$!+`$L``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$! M`0$!`0$!`0$!`0$!`0$!`0("`0$"`0$!`@("`@("`@("`0("`@("`@("`@+_ MVP!#`0$!`0$!`0$!`0$"`0$!`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@("`@("`@("`@("`@("`@("`@+_P``1"`#,`6T#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H MHHH`****`"BBB@`HHS2$XZ_3ZT7Z`&>WZ^A/08KQ?X\?M$_`_P#9D\`ZE\3O MCY\3_"'PM\$Z:C!]9\6ZO;:<+VZ"YCTS1;%W-QKNLR$@16=G%/P_SE?L1_L'_MH_\%U?C-9_M;_MW?$; MQC;?LRZ-K#K82M(NDP>,(-,O87N?AU\&?"D,R0>$?"GWH;_6XK#]$R#@*IB, MX4,QCP_P_AEG6?U-X1=J.'6EYXBHKJ*CNXK79-IM7_;OPM_P5P_:?_X*&_$/ M5?A9_P`$K/V>EM/`.AZC_9OC+]LS]I;2=7L?A9X9C6>V,[>'_!NB.LNMZXUB M99+2PN+[[?+]HCENM,M+:)I)/U]^`O[,FI?#>&#Q3\8_C#\0/VDOC-=Q+)K/ MC[Q_<6FE>'-/N7>PN7L_A[\*?#45MX>\!:/%?Z?%-;FWLI=1#NYFU&4%$C]D M^#_P9^%GP`^'OAWX4_!GP+X=^'/P\\*6IM=#\+>%]/AT[3+0.QDN+B18QOO- M0FG:26XN9VDN+B65I9Y9)&9CZ9P<<]_SYZ?Y]*^;S?-99A/5I+DP])_P`M&DM+ M+^>IS5'O=;`<=_KZ\^U!QWZ?F.O.:\S\8_#S5O%4Z36/Q3^)'@I59F,'A&Z\ M)PP.",!'&N>$KYM@ZC#`Y/6O)+[X%_&>T?4KCPK^UO\`%"TEN+5X]-L_%_@O MX3^+])L;PJ_EW%Q%;^#=-NKZ$$KNB%Y#D(,2+R:^?>C5E>_X??8[,1C,90G: MEE-7%P3MS0J8=:6WM4JP?RM<^I^3D8&.V>_X#I7.Z[X;AU^WF@EU3Q!I;31+ M#]HT/7-0TF>'8^]983:S!!-G@LR-N!VG*\5\$:WH/_!4'X?Z?,?!_P`0?V5/ MVA#&UI,J>.O`'CGX.Z]<[I\7EE:MX5\8ZMI]K&MLW[NXE\QBR?-#V;PGQ1_P M4N_:/^`4ER_[5_\`P3R^+O@?PY;7B1GQ_P#!WQEX>^-W@T:2CW$4^M7MWH]C M9OHX/V6::.TNO+N5MRLDZPDXK.52,;\Z<4NK3:];JZ2\VT?,8_CG)\MA)9_E MV/R:@M)5:V"KU*$>EY8C"QKTH+^].<5KOU/N?5/V>?B.MI?CPI^UU^T'H%_, M+AM.DU.Q^!_BW3M,>8EE4V>O?!U[B_A3<0HFO&<``>9P#7SIXB_9O_X*,Z?> MVM_X`_X*':7JT=M$[W.B_$[]F?X67-AJ-PC!X83>^"+32[BRMF*A79'=U$C, MHW!<:_P*_P""LG[!WQ_:QL/#'QUT+PKXFO1$I$_$RVOOA_K,%Q,9_+M$N_$ M,$6G:K/Y=NS/]@OKM(PZ^8ZLP6OT5MKNVO;>&[LKB"[M;B.*:WN;:5)[>>"5 M5>.:&:)BLL3(P964D$$$9'-"<*L?66D_M@?\$^/C#\,RMW>1:GXHT">^&A3V]F8C-/X8'B;0;?3_$J1"YMA M*\&O>2&F'[U20I_HA[Y)`';^N?QK/U31])URQN=,UO3-/UC3;R/RKO3]4LK: M_LKF(D,8KBUNHF2:/U0Z52W[NO*#\U&2]-4G_Y,>7CN!>*J'-4X M:\3,RR^K>ZIXZGALSH-Z>ZU6I0K*.G2MS:NS5S\C?A'_`,%R?V`/B?\`9(=7 M^('B/X3:G+?A";?PG+ M+3+,ZDZ5=7\ MJI-Y[6\4(N&@YY5L91NZE%5X+=T[IK_MUWO\M/,^$S3C+QNX"4L1Q'P;@^/< MCHZU,7DLJE'$P@K7G4P=7VDFTM9>S3@OYE'5?VN9''IT_'M2U_$[^S3_`,%Z MOVL?@EJ,'A3]H70[/X[>&]+NQI6JMKD,7@WXH:,;.9[6Z3^U[33Q!?ZA`05D M@U"Q\Z9[3RY;R"5Y)Z_IV_9"_P""C/[+G[:.FP1_"KQQ%8^.X[-KK6?A=XLC M_L3QQHYC9DF:.RG/DZ_8@!7%SILUU"(Y5$S03"2&/6AC,/B-(3M+^5Z2_P"# M\KGUW`7CCX?^(,H83+,T_L[.GI+`8U+#XE26\8)MPJM/I2G)]TC[LHI,YZ8Q M@=>O7K],49Z^WU_PKJN?KXM%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`"'T]NOI7X,_\`!;K_`(*[Z/\`\$]? MA4/AC$=2T?6?VLOBAI%TOA/3IA;:E%\+/#%W%<6DOQ,\1Z9Y_-X)ED30[6X M1H;N\@:>>*>SM)X9OTE_;O\`VQ_AY^P?^S)\1?VC?B(8[RW\*V4=CX3\+K=I M:7_CGQYK'F6OA;P?I;LK,;BYO59YY$23[+8V=W>NOE6TA'^9_P##;PA^TC_P M5S_;UTS2M9U:;Q/\7_V@_'D>I>-/%36;1Z/X.\)VHA.MZX]I9PLNF^%=!\)V MBI:P*&_=V%O:J7FD7?\`L'A5P+@\^KXOB;B)JCPKP\G4JN>D:]2"4W3O_)"- MI5;7O>,+>\[?EWB+Q?B,IIX?A_)+U.(,XM&'+K*E";Y5)6VG-Z0OM9RZ*_WA M_P`$??\`@E_\2/\`@JE^T'XC^/?Q^UO7=1^`7A'QLVN_&;QKKNI7USXL^+_C MK5&EUR3P3HVI7"NUU M#/!F@Z5X7\*>&-*LM$\/>'M#L;?3=)T?2=.MTM;'3]/L;6-8[>VC@C1550!Q M]37DW[,/[./PR_9+^!?PZ_9^^$6D1:1X)^'/A^ST:S8PP)J.MWZQB36/$VO3 MV\:"^\0:EJ37%W>3D?/-"PR]V%*D MK)2<59>TFDG+^56@M(Z^]P5PEA^%LM4)VQ&:XRT\57>LIS>O*I/7E@W9:^\[ MR>KT\XU+QOXCT_6)=+MOA)\0M9LXVPOB'3;[X8QZ/."A^M-(4D@KD'N0"#QZGMTKX+T/H\1AL?.,OJV8 M^QFVVN:C"<5JK)KW)-)77Q)N^Y\K>`?VX?V2/B7JZ>'?"7[0'PUN/$TE^FE0 M^%]9\0V_A3Q/=:E)OVV5CX<\5_8KV_N`T4JE8()-K1LIPP(KZD@N+>ZB2>VG MAN8)4#QRP2QS12(PR'22-B'4CH02,=*\"^.7[*7[.G[2>DSZ+\;OA#X+^($, M]N;:/4-5TM;?Q!8QB.:)&TKQ1IDD&I:1.B7,_ER6MU#)&9&9&4G-?C#\7_V` M/VV_V)(K[XF?\$V_V@_'_B?P-H\)O=4_9C^(MW%XTMVTZPA22:V\(QZX9+;6 M0;.PL[>&SC@L=5C57CL]1E,Y@7*4ZE.S&H<4Y32NZE7*Y2AC*<%O/ZAB)255):M4<5.IVI-;?T0\9Q[>G84R2.. M5'CE1)(Y%*O&X#HX8;2C*PPRD<$8P1UK\(/V'_\`@MW\./C7XEL/@K^U!X:C M_9^^-K:C'X=M[V_DNK;P)XFUYIY;=-,D?5(4G\#:XTZI$+34&>"29U2&\\V5 M+9/W?CECF1)8W22.1%DC=&5T9&`975E."I!&#WITJU*M'FIS4U^*?9IZIKS/ MC-*I2FMG&<5?>+:U/S6_:O_X) M0?L>_M96^I:GK_@"V^'7Q$O(Y9+?XE?#*WT_PSKS7[F:6.[UVPAM#9>)T:XF M8S_;+=KF520MS$XCEC_GW^*GP>_X*>?\$<]3?QE\*OB?K/Q)_9RAOX9$OXXM M3\4_#_3X)KOR(;#Q]\/M4D?_`(0>ZN+W5'B-WITZ07+W$3)J$=WLA@_LUJCJ M6FZ=K%A>:5JUC9ZGIFH6\MI?Z?J%M#>65Y:SHT(ZE3.,BK5."N+H>]2S++9/#S%L]141'S(D@O[F5S&G[KQR1RHDL3I)' M(JNDD;!T=&`965E.&4J001U!K^-[_@KS_P`$B&^!+:U^TS^S+H-U%+"UMYM3N(4N#;6GCG2(D2/Q3I[2W`WS.8]0C6&-8;Q8D\EOXI_VB_V M:?VA_P!@SXTVGA+XA0:CX,\::'5G@O(H]P`AN[.>,+/%$^W/^D]7R=^V/^QU\(_VU?A#JOPL^*>EHLZI=7_@ MKQE9PH?$/@/Q0UL\-IX@T68E?,`)1;JU=O(O(`89A]QT\_&8&&(3J0?LZZV? M1OI?]&M4?S;XS?1]R;CO#U\_X9I0R'C?#+VE.M2_=4\7*/O*%=0M:HVO&)(9&)%_'&^Z[D_/?V:?+^,5]H=U\3OV;F:TD^ M(Y\-6GVSQ]\'M/G,8NOB/I]O;.$\9?#"VMD:XU6V53JVFK++>6KWUB/L=E_` M!^U-^S1\1/V2?C7XQ^"7Q+LV75_#-])_9>M16T]OI7B_PY/)(=&\5Z$9QF33 M+RV0,!EF@E26VE/FPN*_HN_X(E_\%'(O'NF1?L)_M$WUMK"7>A:EIOP@\2>) M;I+I?$&BFW^SW_PEUB*ZA(O94TN2]ETUY'82VL$U@XW1VRR\V"QM1S>$Q,G& MLG:,GJ[_`,LEU\GUVO>S/R/P<\;>))X^IX5>(6.J99Q'A9RH9?CZZ_>1Q5)V MC@\0WVFZGI]X@D@N+:X@8AE*D@@X965D8!E('5U_,'_P29^/]Q\'OV]_ MVI_V"=(UFXU?X'Q?$#XNZC\&[&ZOK:[M_"=[X%\6:G%=V>ASQ)\VGZCX?999 M(4/D++HBW$*1/-3!A;6L6<&:YD52+>W M7J\C[8T'S.R@9KTZ-95H'O&V'XXX<_M=0CAL7@ M:^(P>,IJ5X4\5A)^SK\@@NK.>"ZM;F& M.XM[FWE2:">"9%DAFAEC)66)XV5E8$A@P()%3UL?=)II-.Z>S74****!A111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!29QUXXSU_/\!2U\ M#+69X%;5?B#K40T/P+I<:S!O M,67Q1J&F&;$C"86OCL7A<%AH>TQ&,J0I4X_P`TYR48KYMH MY\7BJ6"PN(QE>7)0PL)5)OM&*;;^Y'\0O_!R9^WK=_M'?M;M^S)X-UAY/A-^ MRSWM;@-9Z_P#&B<^3XVU*Y,3LLITB-(-&A0Y:"XL]2)(:8HG[)?\` M!KQ^PW;?"_\`9_\`%G[:?C/1A%XZ^/LU[X2^',M];1K>Z3$O"^KF&^O[0RQ M^;:IK?B_3I9#@JL]IX;L+A=\4L;'^'/PIX>\;?'WXQ>'O"]K>'6?B%\9?B-I MFBQ:CJ;R8U'Q;X^\1PV9U'4Y;>!VCA?5=4,UPZQMM1G<(0N#_KU_!/X3>%?@ M1\(?AI\&/!%K]D$_"_P1X;\#Z%$4@CEDL/#NEVVFQWETMK#'&U]<-`\]PR1 MHKSW$CA5W8'],^+%:EP/P%PYP%EDN26.CS8F2T#YXU_]J";X5NT?Q\^%?CWX?Z5;H6N_ MB-X2TC5?BM\)XU`NF:YN?$7A#23JOAZRQ;Q*9M:T/2XEDNXX][9#E-I;[=SS M\7F>%P%WC9O"T$OXLXOV22W9]98XQ^%(1G/&>./?J_%/SZ'30Q.'Q5.-7#5X8BG*S4H24DT]FG%M'\_ M?_!9O_@F+HWQW\#:_P#M0?!/PY;V'QV\":5)J_C?2]'BMK,?%#P?HMD7O9[B MV5%^V^-M.TZU#6DP837=K:FP*SRK8K%\Y?\`!#C_`(*8ZSXCOM+_`&,?CQXD MN]4U(6KQ_`GQ?K=UYUS-::58R37'PWU?4;NXWW,T5E;%]&+;G*02V&X[;.,_ MU'.`RLK@;2"K`C(*G((_*OX)?^"I_P`#-6_8;_;^U'Q7\*IYO">F>*-5TKX^ M_"R\L(XTC\/ZE?ZU%JQQ ME)6BVE4BMI)[/LFN_>S[W_DSQCRS$>$G%F3>,_"=-X?`XS$T\+G^#I^[2Q-. MJ_=KN":BJDK.+F_^7RI3O>4^;^]V@@'K_GM_6O&OV>/BYIGQZ^!GPH^,FDHD M-G\2/`OA[Q4+:-Y)$LKO4]/AEU+3TEFAC:=;?4?M4'F&--_V?>%`85[(2!U- M>FFFDT[IG]8X+%T,?@\+CL+-5<-C:<*M.2VE"I%3A)>3BTRAJVDZ;KNEZCHN ML6-KJ6DZO8W>FZGIU["EQ9WUA?6\EK>6EU;R@K/;R6\LB.C`AE<@@BO\^;_@ MJ;^Q9)^Q3^T_K_A3P_:31?";Q_%-XV^$]RXE=+;0;N?9J7A9YYG,M'UVVNF*)<+ MX9\;:EIG@WQ#80M]F=Y$EU&]\,SO&'B0_P!E+*['R54\.8T%7PTW:\Z7O1^6 MZ^:_%(_`OI*\`X;C'PYS+,J5%?VWPI"6-PU1+WG3A9XFBWORSI*4TO\`GY3@ M^YA_\$(?VVK_`./GP+U7]G[X@:L^H?$;X"6VFVN@7UY*\EWKOPJN(X[+P^99 M'&9KW2KN&:PD.3_HIL"Q_P20^-]Q\"OV]?@?K! MO5LM&\=:S+\)_$JRS2Q6UWI?C]8M+LK>X$2DS!/$\?AVXB0X4W%C"6(4&O\` M0?N+NULX9;B[N;>VMX8WFEGN)HH(8HXP6DDDED8+'&%!)8D``$D@49=6=?#Q MOK.G[K[NUFG]W7R9G]&;CS$<9>&N'IYIB/:YGPQ5>!JSE+WITHQC+#U)M]?9 M/V;;=Y.FV]RS0<\X]./K7R1\5/V]/V-?@J;J'XD_M)_"/0=1LC:_:=`M_&&E M^(/%4:WO_'M+_P`(EX;FO-3:W8$5G:2X@4M5]?N5W]R/TWB+Q0\/^%HS_`+;XKP>&K0O^YC6C6Q#:Z*A1 ML:)KFCW=QI^J:1JNGW$=W8:CIU];2++9WD-U%&\%M;ETF>6YTRXN]-EV"[T^>>"*26RFB,4L1DCCDV2@21HX*CP!_ATCZG:ZIJ^N^(=3N5C\<>)=:5EEEL1!$HMX#++'X-CXEM]0T/Q=]DM7.R"PM]0T;PW(Q0`M-K[%L_+7] M/G.3TQV]??->O@%!82DX*RDKO_%>TG]Z?RW/[>^C?ALEH^$/#%;)X2BL>JU7 M%N"?&[KJ'C#]ACX M\>)K[3O%?@T(]YJO[/\`\0)8UO;R_P#ANIF4Q>$=2C^V:B=%PUJEQ;:BMI]D MDEMDF_:#PAXM\.^/?"OASQMX0U:TUWPMXMT33/$7A[6;%_-L]3T;6+*'4-.O MK9^"8I;2XB=<@$!\,`<@?F%_P6T\-Z+K_P#P3?\`CQ>ZK91W=UX6N?ASX@\/ MRO++&UAK!^)7A+1#>((Y%$C_`-EZUJ<6UPR8NB=NY58?('_!NM\;/%?CG]G# MXK?"+Q'=R:CI?P9\=Z5+X-N9Y8VFL?#WC[3[Z_F\/1QB!6-C;:[HFK743O)( MW_%0M`NR*")!2J^SQ7U=N\:D>:/DTVG'TTNNVRTL&!XLQ'"WC++PUKU7B,EX MHP#S/+D[N6#K0=98C#)O_F'J*A4K4H[4I/DA:,E%?T/T445UG[J%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?R'_`/!V%^T?+X>^$'[. M?[+.B:D8;GXC>+=;^+'CFTBEN4=_#7@2UBT3PA:W,9MC#=6=WXDU[5;G(F$T M,WA"'*&.;-?UX5_FR?\`!R/\9YOBE_P5!^)'A*"X%QHGP.\"_#;X9::T&I-? MVS\?>)+B.`?)IU['K7C2YTZYB7)\SP\&<[B47]:\$\GCFW'V75:D. M>EE%.IBG=:<3\T\6,SEEW!V,IPERU,RG"@O\,GS3^3C%Q?D MSQ#_`((-?#*R^*?_``57_91TC4X[UM.\->(?&/Q&N);.,2+;W/P[^'7BWQ=H M;7I92(["7Q'I6CV\A;@_;0@^=EK_`%"1TY[*OAI;M)$2#Y;F">5"PP=LK+T)%?Z)M>M](#%SQ''5 M.@[J&"P=&"5]+RE4J-^5^=*W]VYYO@OAH4N$ZU=:SQ6*J-ORC&G"*^5F_F%% M%(<^Q(]N?SSQ7X>?KHIY_P`]N_Z4UD1@0RA@PPP(R""",$'MBN)UOXC>#?"^ MO:1X<\3ZY:>'-1\0O/#X=?7)!IVGZ]=VL,5QH(ZC%):WL91JTJDITXU(SG3TE%--Q?\` M>6ZOTON?(7Q6_8/_`&4_C%?S:]XD^$6@Z'XRGCD0?$#X>O>_#?QZDAB\JWFF M\5>";FQNM2,!VR6\5Z]S!%+&LBQ;AFO#;K]AO]H;P7>1W?P'_P""A/[0?AFP MAU5M2_X17XW:?X=_:*T"2V6T\F/2(M2\6&RUNTL_-2)B#J\T2C=L@#,6K],: M*EPBW>UGW5T_O5F?.XS@[AS&U95WERP>)D[NKA:E7!U6[WNZF%G1FW?=MN_6 MY^4[V?\`P6+\"VUE;6.L?L5_'0RZE-)>ZAKNG?$3X:ZI!IH<&*")=%NI+4S/ M$"H;[/(8V.6,JC:?Y^/^"Y'Q(_:.\;:Y\`]+_:7_`&;_``U\$O$GA^U^(2>$ M/%'A#XQ:1\2M!\?:1<3>$_\`A(&M])M=%M+WP_%;7\6C-$=0"22"\E6*-\2, MG]KQ(4$D@`#))Z`#J3^%?PE_\%5OBSK'[=G_``44_P"%9?!^)/%5OX2OM&_9 M]^'G]F2-=6.N:Y:ZW>-XCU:&YMA(LVGGQ1JFJ*;N-71K32DF5I(5C<\&8KEP MSIJCMZ'\W?24R^.2>'<\JP_$>9X_&<2XO"X3#8"O7 MI8J-::K0JMKVM">*;A[--2C74N>4$VXOE?ZJ_P#!-;]M;]HKX-_L8_!SP(/V M%?VG?C?H^EV?B27PS\1_!%CIEYX>UOPY?>+==OM(M].%TZRP6MI97$%H@?AQ M9;TRA4G[GE_X*4_M#B)S#_P2[_;(>8*?+671=(2-G[*[HS%5]2%./0FOT;^` M/PDT;X#?!3X7?!O0&$NE_#CP3X?\*0W.QHC>S:780PWVHM$\KF%[F^%S.R;V M"&X*J=H%>O5UTZ52%.$'6;<$EM'HDNWEI?YWU/U_A?@CBW*.&LARJ7'V*P\\ MOP>'HN"P>`FJ;A2A%PC.=!RDH-.,93;DTDY79^&^L?\`!3/]O3[='!X7_P"" M2OQRO;2201I-XA\3:CHDZ[G"QF1+7X>W4,*;2I=FF"IDY;:-U?('[=7[77_! M4#Q;^RW\:Y/B=^P?X`^#O[/>O^#YO#/C;7/%_C[1O$WB[P[9^*+RPT#3-4TV MR7QCIMQ-JT6MZEIYM2NA7'EW#1.R`1,:_J'K^=G_`(.(_P!H:W\%_L\_#W]G MO3-2C7Q!\9?%9\0Z_IUO=D7,'@CP!):W@?4;>&7*6EWXIOM&%N)D\NX?1;EH MF+V3@88F,Z="M4GB9N,8O2T%JU9+X+ZMI6_$^,\5,HSWAK@#BW/,W\4,TQ>% MP^$JQC05#*J$*E6LO8TJ,I4L%&I*%2=2,91Y[V;LT]5_(Q$[7QI>_%;X8V? MPWO&T_XA7GQ#\&6W@*^W0@V7C.?Q'IL7A>\#7,4D8,6MM8OF1'3Y/F1ERM?U M)ZA_P1@_;Z^.%_:-^TI_P4(UW5='FBO;JYLH-4^(?CK^RKS44'VJSTOP_JWB M#2]/M[%SE'6!H(A&H58=H"#\=O\`@CC^SQ>_'_\`;I^%S3:?]K$_".:3XN^ M+;J:U%Q8V\?A62$^&[65F95%Y<>++G1EA4-Y@6":X1&6WDV_Z`0Z#\.#VXZ5 MPY9A85*,YU+N,W9)2DD[6UT:OV6^Q^$_1A\)'H M4L9B<-0K*C37MIU(4)T_:^_-4XR7UO;.T$;& M"*>.`."RQJ2:^Q:*]:GAZ%*WLZ48M=;*_P!^_P")_8G#_A=X>\+RC4R3A#`X M.O"UJKHQJUM-G[:M[2K==^:]];W&!%10J*J````#```PJ@#H*_SG_P#@IS(D MG[?O[5K1NDB'XN:Z`R,'7*PV:L`5.,AE(/H5Q7^@O\9?BEX8^"/PK\??%OQG M\=^+/$/B_5S;J\5NNI>)-6N]7O([:*25VAMEGO'6 M)"[;(U5=QQFO.S>I%4J5/[4Y7]+*WXN7X,_F#Z:&=8.GD7!_#B:>.Q&)JXOE M3UA1I4_9)M=ISJ-)_P!QVOK;^@7_`(-NH)V_:0^/5RL4K6\7P7L89)Q&YACF MF\::.\$,DF-J2ND$[*I.6$#E>%8U_8K+(D2-+*ZQQ1HSR.[*J*B@LS.S$`*% M!.>W4U_*I_P2@^+'[.7_``3@_9&\8?'3]HKX@:?H'C[]HC4]*\0>'OAGIKIJ MWQ*U3X?^#AJVE>#+FR\%P78GM+>_U#6/$]W!>W:V=I-:W4$AN6A6*2OAO]NW M_@L_\>OVO3J?PG^"NF:M\(/@WK;W&E/HND2277Q,^(%E=BYM#8^)M4TN9ULM M/N;.91)I6G;T9I'CGO;Z/8%JAB:6$P=&%5WJV;Y%K+5W2\M&M_Q.WPZ\4.%? M!KP;X9R_/,7_`&CQ1C85L52RO#-3Q/\`M56=2A&JE=44Z;IRDZEI+F:C";5C MZ,_X+C_\%)O#'QFEMOV2?@7K]IKW@;PUK<6K?%KQGI4TDVG>)/$FE,#I/A+1 M+N(B*_T:PN6DN+R=#+'/>Q010NBVDIF_3;_@@C^S!XE^!O[*>N?$[QG:7>EZ M]^T/X@TKQCI&DW#H/LOP^T723:>#+Y[=06ANK^34]=OA'V4I1@I)3FZE2K M-1O%%BBBBO2/ZL"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`$)P"?0$_E7^1[_`,%"O']Q\4?VY_VN/'=U91Z?-K_[0GQ6D>TBD\V.'[!X MQU72U"O@;MR6*N>.LE?ZVVI.T>G:A(A(>.RNG0CJ&6"1E//N!7^,UKVN:IXG MUS6?$>MW4E]K.OZKJ.MZO>S,6FO-3U:\FO[^[E8YW227<\SL<]6K^EOHWX2, M\RXGQSM>A1P]+S_>U*D_N_K))8Z]XO\2?#JZ1;Q+* M'/Q,\!^*?`MC<74DC!9;:WU37K&Z,;<.UD@3]YM(_P!1P=!SGCKZ\5\U](#! MSP_&]'$O6GCL%1FGYPE4IR2]%&+?^(]SP7Q4*W"E>@OCPN*J)KRG"G)/YW:^ M0M``&<=SG\:**_#C]>.:\7^#?"GC_P`.ZGX2\;^'=&\5^&-:@^S:KH.OZ=:Z MII=_!N601W-G>1.DH$D:.I(RKQJRD,H(_/WQ3^RO^TW\&)9-;_8L_:'N+;P] M:JLR?LY_M$)JOQ,^'%P(IK=WLO"'Q#O-0?Q-X!B:TMS#%;&ZU&P#3LXAMG=[ MD?I.?7TYIN0,Y8#N].?-3E]J#/QTO_P#@IU\8O@#(=/\`VV?V(OBW\+;2S\Q+ MCXJ?"&\M/C)\*=0BM[:XDEU9+W3;>WG\.PRR6EQ(EE^ M$W_!3;]A+XU-96_@C]I/X=IJM].EK!H'BV_N?`>O/=FU%W);PZ5XUM;"6\"1 ME@TUNLUN6C94F8@UZA^T'^UW^S'^SAHUS#?#3364LT?A6XNH];\5Z MS:F.XW1Z=X-TJ.XO]323[/-&-ELT;.ICW;R%K^>C]H[X4^/O^"GVN"Q_90_X M)Z^"/@GX%U.\:ZU3]JKXW>#+;X7>+]?CNQ'<3:MIFEZ(J3:C!<6_V-H;F6VU MRZE2<-&UDC2R+SSG5I749JM/I%KWOFXZ)>;BEW=S\?XDXHXKX,JO!Y)Q)0X_ MQ[:]GE57!RJ9G+HHO$Y=RT:4;[UL5AH176;>_P!8_P#!6G_@K%X4^#G@G5?V M>OV:O%&F>-/C?\0M)?1M8\4^$M435;'X8Z!X@LS$EUI]]I!ECO\`QU=VMT@L M((I2UF+A;V7YQ;PS"3P[H:0P:M8WT M+B/RKP:\C!X_,$"'"+V5[_P37_X*G_#FWUR#X*_\%,O$OB.Q,IET:R^*-QXI MO-0O,$`+?ZUK4OB!M+.,G%NDB=MM8*&(==5\10&\0O$;PZQ.=PRJDGE.7Y=C,%6HYM_$SXL3? M##PIX*\.VIN]7URZB_9YGAM8S)'#%$L-IJ3RW-W+/+%'##$CRS22K'$CN0M; MRQ7+%REAZJ2W?(K+YJ37XGZCCO&JAE.&K8K-O#KB?`4\+!SJR>74I4Z<5JY2 MJ1Q7+9+5N^FMS^H#XB_$+PC\*?`WBKXC^/=:M/#O@[P7H>H>(?$6LWQ806.E MZ9;R7-S+MC5GGE*1[8XHU>661TCC1G=5/^=O^WA^UAXF_;>_:<\9?%N>#4(M M!O[V#PO\+_"C)YL^A>"],D-GH6G10PIF?5;R=Y[VZX=GO-5ECC(A2&./M?V@ MO^"C?[;7[:WAS0O@W\2?'EUXIT._\1Z?-8^"O!'A/2_#\WBO7Y9!9Z+I^H6/ MA6PCF\28O+A#:V';C[=X;U#7?!?A_7;72M0EA:.UUB#3=>EEMX]3MS+YMM/)$7M9XTGB*31Q MNOE8O%/&\M.C3FZ$6G)J-VWZ*^W2[5WZ(_D?Q@\5\R\;YY9D/!F0YM/@K+ZM M.KC:E+!3KXBI5>BYJ5"4X*-*',Z4)58\\VY-I*-OZG?^".W["4W[''[.W]O^ M.]-CM_C;\93I_BKQLL@W77AC0A9POX7\!YQB.6SBFN;B]VY)O]3FC:1X[>`) M^N^Y5&20!C/S$#`//4U_(=8^!_\`@XJ\92S7\.N?$30UEW,+2^\4_!KPM'&, MJNV&TU">,QC#<`<\''2L.P_X)P_\%Q_BQ+K"^.?C[XM\&VVI)*M_9^,OVI?% M8T;4XY,"2W31?AO>:M:QV[AF_=M;QQX0@@<9[X5W2ITX4<%5<8I+6*7WN[U; MW\S]_P"%_$O$<+\.Y/PUPAX*<28G!9=25*G[7#T\/S-*\JM24G*\ZDW*=1M+ MWFVKG]<'B3X@>!?!L<,OB[QIX3\+1W+,MM)XC\0Z3HB7#(,LL#:G=Q"9@.H7 M.,5\1?$O_@JQ_P`$_OA5%+_PD/[3'@'5KZ,7R+I/@9]4^(6H/=V$;,]E-'X* MT^^32YWD4)$U[);1.[`>8`&*_@9X:_X-U_VF_$MM9S_%3]H_X>:7HZM'IGF73*9/E:W09QER":^)_^"@O[%7[(?["]C+\,]-^ M.GQ"^./[2>I26=Y%H6C6OA3PGX)^'.@3Q"4W?Q`MEM=5N]1UJYB9#86%M?V$ MOER"ZNML'D+=S5Q>*C"53ZM&C376_!_[ M7OPYT;X#?L]V?C'2?AU=ZS!KOQ(UOQ190Z'<^*SHTUG?>&M!M--MK^9SI4.K MQ/>7(N-H:XTVR>-6*$I^)WPE^`WQG^/&LMX?^#7PN\;_`!*U:+R_M5MX0\/Z MAK"6*2S11+-J-W;0(-TT>Z2XDCC127=E0%AZC^R1^QO\`&S]L[XFV/PY^ M$'A^6XACN+9O%GC348;B'PCX&TF7S'DU3Q#J:1%8W,$-P;:T0FYO)(O*@1CN M9?[\OV-?V._A9^Q1\&M(^$GPSMI+I@XU3QAXOU*&W&O^-_%$\2)>ZWJLL$8$ M4(*".TM5)CL[9$A0NWF2R<%'#ULRJ.OB),_#GP-T5VMGOM+CFM_B/X_EMHU>/['';:1JJ:78S"*W MAC$KZG<+`EQ&ZP7'EM!7]'7[(_\`P3#_`&2_V.DL]7^'_@2/Q-\18+=8;CXI M>.VBU_Q>S;(_-.E&2);3PU"TJ%BNGV]NS;@LLDH1-OZ%8'3'K_G/K2UZ]#!8 M?#V<*=YK[3U?^2^21_:/`_@7X<+RO)%CLVI[8S&R^LXA-:G"ZB5@9K8WEE")%!&Y"RDX.1_L,_"WXA:!\6?AMX` M^*'A6>2Y\-?$7P9X9\;Z%-,J).=(\4:-9ZSIXN8HY'$-T+:\C65`S;)%9-/V:?$^L?"G5(WS MYLOA*XE;Q/\`#V^PEG'''$NAZK+I@59)Y6;PN\\SJ;A5'J_2)R.6(RC)L_I4 MW)Y;5G0JM+:G747!M_RJI34=>M16W9YG@EF\?SSI]S:?!&/PO#K%H M"JHIU".[EV)M,I#/N^A?\_E11^1S8G!X;&14,325:%FN5MV:>Z:32:?9IGS[ M\/?V4_V;_A7J]QXB\`_!/X<^&_$EU?MJMQXGM?#5A<>)KC4Y(VBFU*7Q#?QR MWK7TB2/YDIG\R0R,79B37T`JJHPH`'^R`!^E#$C&,?B<$_3WKS/QQIGQCO[B M`_#GQM\./"]F(F6ZB\9?#'Q+XXNY)CD++;76C?%GP^EL@Z[7@F_WJ222LE;[ ME_DC"GA<%E5%K`9;"C3NW[/#TJ<+MO5\JY(MO=ML]-/3Z<^G3FN!^('Q5^&? MPHT67Q'\3_B!X+^'V@VZ&276?&GB;1_#.EQJLD43,U]K-Y#&%$MQ`I.[@S*. MK#/S+XH_9B^.?Q`TP6/BS]MSXV^&WD:[2\7X->%OA7\-[:YLKQ#'):1W5_X0 MUG4[%D0L(;B#5([J$G?',L@#CQJW_P""1'[&VJZ[<>)_BKHWQ,^/WB"[CMC/ MJWQO^+WQ!\=7;7<"1(U]ON=P(`*B3GKR03:[RLOP4O MT/G\PS/C"HG3R/AFC&;6E7'XR%*DK]?9X6&)K2MLXOV=^DK:GR9^T5_P7@^" M_A^[N_`7[)'@3Q7^TW\3+DM:Z9?:1I.K:?X(MKJ6-(H;E`M@^J>)E6\N+>,0 M6MG#',2P%]'^[,OYNW7["'_!5C_@J)XRT[QU^U7K$_P4\`07D^/M/DT M6U\*:?=R!9(?"7PSK"/M-\P=7;^KKX:_`?X)?!JR& MG_"?X2?#;X;6>Z61H/!'@KPYX862298EGFE;1].A::9Q#%YCL2SE`7+$5ZP. M."1P.@]/7FL)X:59_P"T57*'\D?=CTW=W*7S:/SS,O"?/>.*L9>)?&=7,?/4Q.)2:WE.'>*BS\WOV*O^"6_[,/[$\4.N>$/#\OCC MXK26[P7WQ7\;+%J'B&.*4V[26?AVP51:>%K(O;AB;2(74GF,L]U-&(T3](,$ M8`[]2?;Z5C:]XC\/>%M+O-9\2Z[I'AW1M/A-Q?ZMK>I6>E:;8VZD!I[N_OID MBMH02,L[JHSUKX)^)7_!4W]B_P"'VHW7AG2?B;=?&'Q[`+L6_P`/O@1X9U[X MM>)]0FL&@-U;PGPG9S6-DRQ3>8'O+ZUA=(9-DC,NVMTJ=&*C[M*"V5TE^A^A M82/!'A]E5/+<)+`\,Y9A5[M)2ITKMV]YJ_/4G)V7,^:&/A_X2TQ"]YKWBK6;+1M/C;^"WBFO9E^TWCMM6." M(/-*[A(T9V53^*WC;]O#_@IE^T'NT3]C#]A'Q/\`#[1-2@::S^*O[0,NG>'[ MA;#[4;5KZP\/^(-0TVRL[E0T$OE2W&ISM&952P9D60^#Z;_P11_:?_:?\4VO MQ!_X*#_M?Z[XENC+YK>#?`<]UKRZ?$GVZW6QT+4?$%K;Z3X2M?+6QFQ8Z'(L MANKE71)W:Y?*=:335"C*K+NURP^^5F_^W4UYGQN9^)N<9BI83PZX*QW$^+GI M'%XFE/+LLA>UINOBE3J5HJ]W&A3E=?;6AX_^W9_P7GU_QC+J7P?_`&%M-UFR M74))M(N?C/?Z2TWB/53*]U:SV_PU\)SVLLEB'A\AH=2NT%X#*WV>QMGCCN6^ M:?V-O^"'W[2/[2.O0?$S]JJ\\1?!KP+J=Z=8U6R\3+/=?&?QL]RZW%P7TS5' M:3PLTQ=C+=:J&NU8%1I[EC+'_4'^S/\`\$]OV2?V3((9OA'\)/#]MXH2,PS? M$'Q)`GB?Q[<*TBR/$GB;5TDFTRV,D<):"S^S0,UNCO&SH&K[6``Z5@L'*O-5 M,9/VC6T(W4(_J_7KUN?%8?P,SGC7.*'$OC1Q'_K%6P[YL/E&#YZ.689.SY&_ M=G5V2F[0<[6G.HM_$O@%^SK\'?V8OAYIOPO^"G@K3/!?A+3BL\EO9B6XO]7U M(P0V\^LZ_JMW(]QK6L3);P^;<7$CNPC500BHB^V8_P`?KU_3FEZT=*[TE%)1 M2BET2LON1_1V"P6$R["X?`X##4\'@\+%0ITJ45"G3A%6481BDDET204444SJ M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**C\Z+_GK'_WVO^-. M5T;[K*W^ZP/\C19]B5.#=E--^J'4=:1C@$^GK7F&M_&WX-^&M4NM$\1?%;X; MZ!K-BZQWFDZSXV\-:9J5I(R+(L=S97FI)+;N8W4@,@X8$<&@QKXK"X6*GBL3 M3PT).R=2<8)OLG)I-^1ZAD9Q_G_ZW6DR,X[]O?WJK8WUEJ5I;7^G7EK?V5Y! M%=6EY9SQ7-K\VEKTUU.SN8A/;W$+?=FAEB;Z2(R']#7^.G\=_!]A\/ M/C?\8_`&ED_V;X'^*?Q!\'Z?N5D8V'AKQ;J^C69*LQ*_Z/91<9..F37^PAX: M\7>%?&>G#5_"/B30?%.D/+);IJ?A[5[#6=/:>';YT`O-.N)(VF0LNY0V5W#( M&:_RQ?\`@L7\.KGX6_\`!3G]LSPI<:7:Z-'+\8M3\6Z=86>/L\>A_$+2]*\? M:#.H'W&FT;Q+8SLO\+7)4\@U_1OT(<`Y\OUK"TZJ5UJZ-7EVW=E6> MW1N_0_#_`!MI4\3D^1YA1E&M3I5ZD%.+4E:K34DU)75FZ:]3\T_ZU_0?_P`& MW7[85O\`LV_MZV/PK\4:I#8>`?VJM&M/A3<"\GMK>TA^)-OJ`U#X6WHFN&7_ M`$V?5)M5T6")9!Y\OC)$$$_$.@^*?#M_IS7G"HHR^1^"Y!FU;(LXR_-:-^?!U(R:_FC>TXORE M!M?,_P!F\$'I_G-%?"O_``3<_;`T7]N;]C?X,_M`V,]LOB37?#=OHGQ*TJWD MC=M!^)GAM$TKQEIKI$JB.WDU.%KNU^5"UEJ=LY2-F,:_=7/X_3^F:_S@QV"Q M&78W%Y?BZ;I8K!5)TJD7NIPDXR7WK1]4?W/@L71Q^$PV-PTU4P^+A&I!KK&2 M37YZ^84F1T[YQ_6L^ZU;2[*ZT^RO-1L;6\U:YDL]+M;F[@@N-1NXK6>^EM;& M&60-=W"V5K>F*`4HN]FG;303G_)_ M^M2X[_U/\JIK?6+7DM@MY:M?P0Q3S68N(S=Q6]P\J032V^_='"[PS!&(`8Q. M%/RD"Y1:P1E&5^62E;1V>WDSEO%6@:QK]K;V^C^-_$G@B>&`UOX):7XH:UF\2^._BSJ%W;PM!- M/IGQ&\1>"[?4(V(+"_T;P!<:5I\K8`7D:;%Y M&G:7H.D6&CZ=809+>39V6GV\<5M%DL=J*HRQXY.>AHH22V5KF5'*\MPTN?#X M"C1FM>:-*"EW^)*_1=1,=#W'X_7]*6BB@[P_S^/^='^ M`_AOXFS>"-7UK0/%&NV^O:S+K6IZ?$/#>EOJ3VDUM97J2`S!-@<$A"=Q5NA_ M0G]H+]G'_@H__P`$CM+\(?%/PY^TEJ&I_#J_\42:%:OX-\6^*[_PQ9:]=02W ML-OXK^'?BRU.F%+ZTL;@1RJMRS&UEC9HCL:3\X_V(?VH_%'[&_Q[TCX[^$/! M5CX^U;P_X=\3:5_8&IW&H6UBUIXBTYM+GO;BYTR-Y(1$)E*\;2S`$C(K[F_: MN_;^_;`_X*J:5X'^"/A#X#/;:!;>*X]8@\,_#'1_$WB:[\1>)(["Z@TZ35]8 MNT,5E:6=E)J\N<0Q(CR33R".%B/EZ$J"P\FI36+N^1Q@6O@/P]I6H^)Y?`]W) M??:='O-6MO&'@^6WN1)/)8P3ZA;)*+M(;I/(?V.O^"$7B/\`:?\`@;X2^/GQ M;^.UYX%N_BEI=GXN\*Z)I'A^/QAJ;^&=522;2]5\2:MJ.LVZI?WMJ;:Y2&+S MC'#=()I!/OBC^SM4_P""*'B/Q+_P3.^'?P3&I:-HG[3W@OQ;XF^-@GGN+EM" MO_$_C+3H-/UKX;:A&5!';7%T)/S.^&O[;?_ M``4]_P""6O\`8?PC^*_@379_A/X8NIM,T/P7\5?"9F\-FQ2:26:V\`_%'2(% MDN-/,EPGE+'?ZA96X3RH+:$^:M=U1-5:=3'0E.E[.*TO:,[+FYE&UFW?OT^7 M[/GN&QF#XFX>S_Z0629EG?#-;),%3HU,.JLL-@\,O&6J:=I%IXS\5^#]7BGATSQ#9ZA)810?8+IH+FW2_$OXZ_&#X]:YI&DZ7XDBT/4/%>M6U[XW\9>*?$LNEPW+-&O/LZPZ_H2:[9!K:Y5()9/[/ECG MALY705_.];>'_P#@J9_P1T\4>++3P?I6M'X47VL1:IJ^OZ=X2M_B#\%?&R6E MF\-KJM]>M8R7/@[4/LN5E4SZ3?-]@VR-/:Q(SUB(4XO#24)59S1R_'\6>`>%PM>7)@*V(Q/L<95J5)>TQ*=:-5 M4H7IQ492BX*G.G\3<)?KK^RQ_P`$5?BW^R=^U+X#^(?@O]JOQ!<_!71Q>:GX MQT711K'@SQ)XGN;&*(Z5X5UC2+'4KG3M7\.W=]/-)**PV1Q^=.LT/\` M.Q_P=`_"$>!/^"C5M\1[;3%L[+XV_!;P%XBN;X7`E?5O$?@U;[X?:C<-"!FU M6+0/#WA.``\.;^E\*W%Y$DUAK4$*323:7,TTA@@:YM[B=%GBMOR?_`.#M M;X/17OPR_9+^/EE9V*7/ASQQXY^$GB"\$6K:O.GSQ6KNFZE."MW?F MF?JU/)O#W$^$N98_PUK.ODD\3#%\KK5JCHU8N%.K2Y*\I3HIZ=K6C7UUI>K:1?V>J:7J5C-);7NGZCI]Q'=V-]:7$1#074-U M%%)&ZD,CQA@00*_U(?\`@CW_`,%!](_X*%?LA>$_'>J:C8GXT_#]+3X?_'+0 MXS96UXGC#2["W,/B^/2K23%KH>NV12]MW6.*W^T?;;6%$-I)&G\D>/O!4L'C MJ7&.`H_[+CW&EBU%:0K))4ZKMTJQ7))Z6G!7NYG](>#?%2Q&%J\+XRK:MA4Z MF&;>LJ;=YTU?K"3YDOY9/I$_G"_:AU_Q[^Q1_P`%C(O&?B/QCXLUC0?#GQF\ M*?$/0M2\1^*-6U)S\+/':1IJ>B_VCK-_>RV^DV>@ZSXET7YCG[-ISF...-T4 M?VX:YXKT/0/"&K>-]3U*TL_#FB^';_Q/?ZM=31VUC;:-I^FS:K-_B M7X'\-_LUS78O;Z2^O/%-NMWX2\97,][-:L9]0F\+>%/$M[<^8!'(TLL0F)9& M;^7*53ZK6QM.;O&/[V-^S6J^^RMY'YYPAGO_`!"SC+QVR#,Z\G@<'2EQ%@54 MDWS4JE-\\(.3UM.=&C=-V<%YG\Q'Q&^./Q0^(/QI^(/[3VGWVO1)>?&9/%_V MN6[F@LM*USQ+K'B#Q7X3TB]M["Z1(YGL?#.I_)#A6729MK#*Y_T8/@?\2M+^ M,?P:^%?Q8T:0OI?Q&^'O@_QK:%UCBECC\2Z!I^K&"XABFD6VNHI+MXY8O,3.ZU]\?\$K_`-L_3O!O_!)?XH^+->N[ M:75?V3(_B%H4&G3FV1KBWGL$\6^`XWMK`^>-.NM4\1FP$\B^9)+IUUL+"'C/ M`\]&IRUI6^L0]KKT=W=6_P`+3?IYH^8\!\9FO`7$F+I<68VK5A%-V36&FIS?=+1*Q^9?[2GQ,^)'[7O\`P6DL_"7P8\>>*O"-O9?$ MKP?\%=%\2>"O$%WH=_I/@WP&J_\`"RM734=$U*W:]M1=)X[O`C2J\L$D=FP+ M`)7[[?M>?\%@OV7OV0]=G^&$!\2?&OXMZ6D=G?>"?AZ;2]BT6]B;R7LO%OBR M\N/)T[5`L,IDMH(KZ^1]@GMHE?S%_FF_X)[2>+/A1\&?VY?^"@LUS-<>-?AW M\/9?AQ\,/$.I3R27A^+WQGUBUL=9\8B9RXO-3TO2[P70BN()8;M]6=6DAD0. M?V`_X(!_LL_#Z^^$/B7]L+QIIMIXS^,'CGQ]XJT/0_$FN)+J-]X5T;1Y;:+5 MGLC>.Z)KNI:Y/?W%S?*/M#0>3`KHOVCSYPU6M-V@[5,4Y5&Y:J$$^6-HZ7;= M[7TVNK'-X5<2\9YEF6(P7#^)IX'B3Q5Q..SRMB\5&>(I9=E%"O+#T7A\*Y1A M.O6J^TC!2M!05-R3BE;>U'_@O-K_`(`EL=3^-7[!?[0/PU\&:OJ<,.F^(=5A MOM,:736`FGELT\4^%M.MM8U!+,F588[R)7`YEC4[Q^N?[*/[:GP`_;-\#7OC M;X'>+)-6716M(?%/A;6+4:/XQ$WE[;-<6]IK^B-/)Y*N([A8KF"2>RN'M)A M;7,PC=A]+>(?#7A_Q;HFH^'/%.B:5XBT'5[2:QU/1M9L+;4=,U"SF7;+;7=C M=QO'/$PZJRD9`]!7\=VB>#)O^">/_!;SPU\-_@]-_9?PR^)7BSP[HR>$(KJ^ MN;.+X>_&*Q$$GAV\$P>6<:1XC=KO3R7>11H]FDLSAKA7['*MAY4G4FJU*I*, M&W%1<7)V3NG:W>ZTZ'['Q!Q!XA>%F9<.XS/^(Z7&W"6?8REE]><\%1P>,P5? M$W5&M!X=^RJT>=/GC./,DDHN[N?I%/\`\'"GP$'B36/"NF?L^?'G7M4T;4-5 ML)XM&M_"FH33#2+J6UNKJ*W@UMI/LP:+<6*C:KC=BO:/V>/^"Y?[)GQT^)NA M?"77-!^)?P:\5>*-3BT;0;SXC:5H5OX6N=6N62*PTN]UK2]=F?1[^XN',<1N MK6*U+[4:Z61T0_SF_P#!,;]HKX0?LO\`[>_C[XJ_&[Q./"O@JU\-?%_1AJ!T MG5M8ENM8U'Q'ITNGZ9;V6CV,\IN)EL[G8S*D0,>'D7(S[;^V5\1;;_@K?^VU M\*-'_8O^&'B>V3PYINE^']<^*DVB-HMY+')J2:O+XR\2O#($T+2=%M(+I+*2 M\GCN[J2!X8-Q:TBKBIXRM*FJGM8SJ\_+[)1]Z2NE=-.ZT>[5C\;R?QQX^Q&3 MTLYAQ;@"_&/C2U^(VM:UHNF0>#VT=9[*?1+"TU">:]_MB_ M@4PO'>(J["S;E.0!S7U;\$OBII/QQ^$GP[^+^@Z??Z3HOQ&$Z-XNTS3-5-N M=2L;/6K..]@MKTVDKQFY2.4*^QF7*\$BOYU_^#CRSET[X*?LD:?/3V'C# MQI9S7;[@]S-;>%/#T,EP^YB=[NA8Y).6ZFOVT_X)[_\`)D/[+7_9$_`7ZZ%: M5WPJ3EBZ])OW*<8-::WE:^I_0_#G&>?9EXQ<<<'8RI!9)D67Y?BO@'Q^&STQ_PDGA[CBOZB;GX!_`W5=/-GJ7P<^%M]:W,"K-;W7@'PK-'(&C M()*/I1^;#-@]1U!S6*GB:N(Q%.G6C2A1<$O\TE;R>*^LC)&R M&ZL+F\M%D(0SAV53Z_\`M-^/T^%7[.GQW^)7EQ3OX$^$7Q%\5PVTURMHMY=Z M'X2U?4;.Q%PS#RI9[NWAA0@AM\ZA,L0#_*M^U#\-M(_X)L_\%?\`X`^(_P!G M>&'PMX3^*5[X*\1GP-IKR1:/INC_`!'\6ZM\-_''A.-+U;A5T*Z-K?W=O`B; M+!KF$6(MC:VI@_;3_@MM\1!X`_X)X?&"",6KW'CW4/!W@&%)KP6DS+K7B6PO M+QK)0,W=REAIEW(8A]Z*&1FPBL:TAB).E7=5)5<-?FM\+LN9-7[KH_,]C)O$ MO.:W!OB=#BFA1PW%?AO'%4,5/#76&Q$OJTJN%Q%)3YI0]LKZ9>^(5GU&^NH[OPUJ8FT7Q=:S)() MC*9O#.JZLAQ&TG[W*8DVL/\`25T^^MM4L;+4K.59[2_M;>\M9DY26WNH4GA= M3W4QNI!]Z_A<\"_LC_\`"8_\$7OB9\>K&T6_\2^#/VC/^$]@6VLK@ZC#X.TK M3=!^'7B6$M!`S75E`-7?4Y"[+!;V^GW4S,&0U_0O_P`$X?VU_#VI_P#!+.R^ M,_C?4XQ/^S-X*\3>!?&IGDMHIYKGX7Z);S^&;&(R0VL,M[?>%[SPG';*&/FS MWZ0M/)<>:1RY,X?XEQC6"XGRFCQ M)@YU).T*:*A>4G=JG&G4=K)*+;U9^)O\`P7P_:5UKXG_M8Z-\"_!6JZG+ MHG[/GA*\_MF#1+BZ5&\8>*M,L/%OBFXN3:(IG2Q\+:?H`E8O+';?9KI/GDE:XD) M$ANO$]_#'DA=MJOH:_'C_@GU\`?&?[7WAK_@I/\`M8^-(X[CQ#JWP<^+WAOP MUJ%X#+;7/Q(^*F@^(=>\3W<#M=;D33="@M8/WD9+CQ+&8Y@\$RM]0_\`!O5X MXLQ\./VUOAQ)'8WUG2=+D$E@^(FG_#.V\*#0_"8\4$3>%KGQW)K!N5,B_8QLU_3-AY\SYA_!7[L> M+_\`@HG^RE^V1^S%^V+X,^`,/B./Q!X6_9U\<^(M9;6_!(\+P?V3+IL^GIY- MT)6^T2?:I4RF.!S6^%KU*M.-2IB8*34O<2CS:7MUOTOML?=>'?B=Q9Q)D>%S M_-?%#+8YC5IXZ;R58"A'$2EAXXA4HJJI*26<],CK7O/P(_P""]O[%WQ=\ M2:1X0\7VWC_X)ZOJ\B6\.K_$#3=%E\#Q7\LBQQ6=QXIT/6[A].#,6_TB]LK2 MU4+AYU8@'XX_X-T?`7@?Q?\`!O\`:.N?%G@WPIXGN++XF^$X+2?Q%X?TG69; M6&3PM/))%;2ZC:2-#&T@!*J0"1D\U]A_\%AOV#O@'XZ_9#^*?Q>\+_#KP7X$ M^*GP:\/GQQHOBSPSH-IH$VHZ-I%^EYXF\.:Q#HD,,>JP7>DW&I&$SH[PWH@E M5U3S5;D<;:+5JZ>]EII8[>&>(O'+,_#G">*%'BK+,UH/" MUL9/*JN6JBYTL/.HJL(XJC44HU'"E*4'R#)=):\2^U;PUXH\3VVI/)JE]#"^G_8O"UTF4 M=F+W4152NYAT_P`$OVQ_A5\8/V4]`_:^U*>7X7_"S6-(\1ZW>W'CN[T^TF\/ MZ?X;\4ZSX3N9-4GL[F6`O+?Z-(84B=V?[5%&JF5ME?R0?&SXT>*?C'_P0^^` M-MXNN9]0O_A)^VO!\(=-U.XECEGOO#V@_!GXA>(?#R/Y<";1::1XJM=.3>97 M9-'61Y&+D+P_[4'Q]US2?^"7?_!/']F_0=7GL]+\6:5\:/B7\0=/@>>$:E8Z M/\;_`!AH_@:UNGCD$=W8_P!K)XIN'B8-MGTBUD!4J,D\L5LL2RW;V MT\,$9:>Z-O:H]POZ"?L&_LA?"_\`9&_9[\`>"O!GAW14\4W_`(9T75_B-XRM M[0/K'C'QAJ&FV=SK6HW6IW2_:'TU;TLEE;,RQ6UM#'&D:D,3]6W_`("\$ZGX MIT/QQJ/A/P]>^,?#5O?6OA_Q1=:183:]HUKJ4;0ZA;:?JSP&:TMY8I'$B(X1 M@YR.371"&*]R53$*][N/(K=+I.ZEIM>^_0_4>'N'/&+$+*<_SCQ&P]*OBI4: MV)RR&6498.%";C*IAZ=7GCB/:1@W&-9N_,M;K5[&N:WI7AS1=7\0ZY?6VF:+ MH>F7^KZMJ5]-':V6GZ9IMK+>7][=W,[*EO;16L,KR.[*J)&S,0`2/R%_95_X M+4?LZ?M8?'S1?@#X3\%?$/PIK7B<:\/"WB'Q8OAVWT?69]$M+C48[-(+/69; MF"\N=-M;F6&,QD@Q%7VX+#B_^"[O[5A^!O[*'_"H_#6JBS^('[0NHR>%8TM[ MB!=0L?A]IODW?C?4$A*M(8[B.33]+W*JX7797659(T1_PR_:1_8Z\4_L`_`O M_@G=^V)X)L+C3OB)8W6EZ[\4+M0_FQ>/[K7)/BEX#74(I[B>%+8>')K[0Y5^ MRI$T7A^%+Q)I;DQUGB,34IU$J:3IT4I5;KI)I)+SM>7H?,^*'BQQ/P_Q:\%P MK2I8G(N":&%QO$;<(SG['%XJE2A0HR=^2K"@YUY.\;1W?NV?]EW[07QFT3]G MGX*?$KXW>(M+U/6]"^&7A74?%>J:1HWV8:K?VFG*K26UB;R:.);@AN/,=5XY M(KP[]AK]MGP-^W=\+-<^*W@#PGXH\'Z1H7C.^\%7&G>+&TIM0EOM/TO2=6DN MX?[)O9X_LIAUB!5RP;=&V1C&?%?VT?BEX>^-_P#P2A^-GQ=\)W$5QX>^(_[, MT_C#36BD$GD1:YH]E?26,^`#'>6\TLL$\;!7BFMWCD5'1E'Q[_P;I`_\,:_$ M8$8_XOWXCYSUSX-\#_TQ6LJL_K5*E%_NYPE+YJUK,^SQ7'&9R\7N$.%L!B:= M3AG/LCQ&8R2A%RJ5(U+4JD:OQ*/(T^5.SW9]^_MA?MNC]G'6K3P5X5\*V'B7 MQ1%X8TCQWXRU_P`27FMV?@KX=^"M=\=:1\._#EUK$?A30M5UGQ#XDUSQCJT> MF:+I6EZ=<2S7:F2[EM+4>+/`7 M_"2>(O"7CFQT3Q!K7ACQ1IYT[Q3X?T?6O"/C#0=?T9K'6M,U/3XV@N;J/[/- M<1'>/2?VX?V.O'OQ=\8R^.OA]:6_BKP[X[\/?"SP-\:?AR-;LO"_B#5]%^$G MQFT+XR^#O%/@SQ#JUM-9'6(=0TS4--OK"]6".\L-3!MKZSN8O,?XJ\0_\$>? M%O[2]M;6?Q3\5ZI\"?AY\._$'Q`E^"W@/1=1T;QMXMM=&^)?C?6O'WB67QEK M.G1V^G6T,5_J6FV6EV5HUW):VND/]KO[N25'%3EB4Y*G!2M:UU97OJF[K3EU MW^+3;0\CBO,?%VAGF:KA?!K$PIJ*PE*I3A]7G>HKRG4E*$?9_5[SNZBK?6FJ M:_=+E?Y*?\&_^FZ=JW[F17]N>D^'?#_A^*2'0=#TC18965I8M)TZST^.1AD!I$M(4#D!CU'/?B!XEC;1]3FM9[VU_L M_P`3^)[RV4M+8VQWB(2+Y>%906S]X9SC!/4'@'UQ@U&#H3PU%4IR4FF]F[:V M[I/\#T_`WPXS'PVX*AP_GLL-BLSABJ];VM#FE%0JJGRI3G"$KKE=TE8^7/VM MOVO_`(.?L6?#?3?BC\:+[6(?#^K^+-'\':;9^'K==OM5U9+NY+V>F37L' MVJVM=-L-0N[DHY=8+)RB22F.-_ST_:1_X*J?\$Q?B7^S?X_T[Q#\2=!^*6F> M+/"_B'2M/^'+>"?$-SXHU/66TVZ&EH-#U_PW&?#UU]O\AK>_O5MX;>4+-YRE M0:_3/X]?LO?`3]I[0[#PY\=_AGX<^(VF:,^H3:(-;BN!>:'<:K:I:7]WH^H6 M5Q%/IEW)!%$/,AD5P848$,BD?GM!_P`$*/\`@G+!KXUG_A5?BV:R5(5C\,S_ M`!3\?2Z"LD19C<[VUW[?*[DKO22^>$A`!$%+!JJ?6N9JE[/D:2][FNN^VC7D M=/'6$\7L9C,=@^$Z60XKAO,*"H\F8+$^WI2E%JK4DH+V52+O:-.S5DKWNT?B M;_P08L;KX5>*_P!J/]K[QCJ%_P"&O@+\*_@QK'A_Q%J%PMS_`&7JVN3:QH'C M".SMBCA-2URPT70'1(4BEG+>*X(XMC7*I+^Z7@G_`(+._P#!.OXC^!+S7]>^ M+]GX0DAT2&[\1>!O'GA;Q#!KT+W5NQN]%M;&+1I[?Q;<(0\;C3)+V.08P3NV MU]Z1?LT_`2#X.']GV'X4>#(?@N]H+*7X<0Z1%!X9F@^V#4'^T64)!GE:^'G/ M([&227YW8L2:_/CQ3_P0V_X)T>)](?#?^G3WM]I'ACXB^-=-T/4? M/9&^QOI]QK$PTRQ0J_EQZ3=]+;)= MKZ^1\?P_P#XH^&W"V1<-\#8K)LYPU"G7GCEF*Q-/VF+Q%5U)2H*G=1H4D^6, M).\]7)1;/YV_V/\`1_"W[0W_``64T/QO^RYX-FT'X.:9\8M5^*EC86FF?V!I M_AOP!HUJ[ZIJ3:8L;1Z!8WFJRL+2QVQK&VLP64<4.%BC_H-_X+W?!*7XW?\` M!+K]I&&QL[F\UCX7:5H_QHTV*V:T1EM_AOJUMJ_B6YFDNU^6T@\&MXDN9%C* MRR"SV(6+;&_07]G;]DW]GS]E'PU<>%?@)\,]"\!:??2I-JMY:&]U+7];EC58 MXGUKQ)K5UVD=_9RZ;XHT6^T2]2ZLIB$O(#;WTF^)B%D4%"0#FO9X9Q53(UP>*I8A\JLER5(R:BNUDUT/HO#?PLQ7!_!W%&49MC*.-S?B[$8K&8E8:# MIX6E5Q%-05+#QDD_9PY4TVEJ]%9*_P#C9'Z8HKOOBK\/]9^$WQ/^(OPM\1VM MW9>(/AMXZ\6^`]+K M/2Q=1PS^)]"NXS=VS[J2NI+JFT?ZRG[ M=/PH\-?MF?L)_%;PWX,O-*\6V_C7X<0_$'X6^(-*DM]2M;_6-$@M?&G@W5-# MOH+6X+07K6-O;L]NOFS6>JS0(Z><37$O@SQM\5_B]X'^$7[$FE!KC1KO]H& M]\0>&+.XO-3\^'Q=\2;/PGX&_L^>%YW@L=$LWTNZNP5MMT$VO:C.Y_>R`_K? M_P`&U?\`P5/2>&S_`."=GQW\1,TR)=7'[,/B'5;F>9IH(X]0U3Q#$;R[N96 M6-8H(GO-!0;$\M;O3T&191-_2'X`_P""8/[$/PP^+.F?&_P/\$]-T/XD:+XA MOO%.D:U!XC\836NFZWJ#7;3W=GHESX@>QA4&]N!%$MN(H0P$2(%4#_./CK@O M,>%N(<1E&,ER^POR5+-*OAI24H3A9/5V:E':,U*-]#]*X^\-\1XV8GA;BWAO M-:64VH_V?G5.1AM"GC_/$O MOB)\1O@)X1_:;_9-D>[T_3O&7Q"\/>'?B#I]PUN)(M1^"OB[Q`#93P1H^+PZ MY':AY(I@%73Y(LR),U?Z5YY)&`>!G/H<^W/_`->OSI\>_P#!*#]@KXF_$+Q) M\4?&?P&TW5?&?C#Q%=^*_$>HQ^)_&NFVVIZ]?W/VW4-0N-(TWQ%#:"2XO&DE MN`L*K-)/(\BLTC$_,8O#5*ZINE-4YPYEK_+))-:)_P"1]/XU^#N<7" M&8T,CQ^14\3@YSJ.<8RP&*HQHU*,>2$V[04HJ+LN6C_`!"^,WPXO_B3J.H2BW#1?$KQ+<6GC;P?'J#2F5(K.U33_"FE MW)C\J1K.QE_U%P[N/S9_X)&_M^>&_P!AF]^)G[%W[9#ZO\*%TCQ[?:AX9UGQ M#INH'3_"'B.Z6"Q\3>%O$7V:.1M,TFXN+2UO[&^$1M7-W.+V"S-A9>()H;K2? M%>G6?F^<+?3_`!5H5S;:A9PB4N0J7`53-)M`\Q]U3P\DZ,Z$E"=%*"33<7'3 M1VUWUNCU,W\)\PR[$<%Y_P"'V8T,JXBX*P$`O$*6ED]Y;Z'X.N[GQ/X MDU8D`0VNF:1IENTDER\K(H\PQQQ[]\TD42O(OX`_L;:!\1O^"F__``5-UO\` M;1O/#NNZ#\$_A7XNMO%-O>7+-'#IL'A+1Y++X5^!;:[E>:*XUR6_MM.U/5H( M&DC1'OMAMUN;8C]N=!_X(I?\$WO#VKV&LV_[/YU"?3YA/%9Z_P#$3XG^(-)G M9>B7VCZOXRFMK^'DY2:)T/<&OTL\'^!_!_P\\+Z7X*\">&=$\(^$M#M39Z1X M=\.Z=::3I.G6S2/*\=I96<2)%OFDEDQSX[@/Q!X]S;(:_B'C)&^+/@+3]+UO2KFUGCGLM5BTZ[UM(YHF^5+F1'^63 M:WJ5MJOQD_X(.?MHWVFW%I=>//V7/C3,+J&!9"MQXJ\$Z3>-'#>6+R,L=C\2 MO#;ZZ(YD?=#>6]\JN\:7L,UK_3W\`?V$OV7/V8O'7BGXE?!3X9P^#?&?C/3; MS2/$>LKX@\4ZQ)?Z??ZM;:Y>6P@UW6;F*V234[.VE8Q1HV857(48KU;XX?L\ M_!?]I'PQI_@SXW?#[0?B'X:TO7],\2Z?IFNPRO':ZQI4QEMKB&:VFCD1'1I8 MKB(.([FWGEM[A)(9'1L(8)PI0Y91AB*+DI? MS??\'`'Q1\#_`!J_9H_8P^*7PWURV\1^"?&OB?QMKF@:O:[E6XL[OPQH+>7/ M!(H>SO8I-\4\$BK)#-"\4BJZD#]$_P!B?_@HE^Q#X`_9)_9W\%>,_P!IGX6> M'/%?ACX3>#=%\0:%J>O-)U6PT>V@O+&\B$!\NXCF1E89."M?;_P`;?V&/ MV6?VAO!G@/X>?%#X3:+JG@GX937T_@;PSHEYJ_@_2/#SZC!';W@L;3PEJ-DJ MQ2111_(P90V7`W,Q/S-_PY:_X)O<'_AGJ#/&<>/OB5Q^7B[_`#FM?98B.(JU MZ;IM58QBTW)6Y;=D^W=GT=3@CQ2RCQ&XAXZX>JY)C9<18'`86M#&2QE-1J86 MC3C4G3C1BVHRJQER*4Y/DM?6Y^&'_!P9\1O`WQ8\5?L??$3X;^)]+\9>"/$G MPY^(MYH7B71)S=:7JMM;^+M%LIYK.?:/,1;NUN(SP,-"1VK]O=1_X+8_\$X= M)TN6\'QXGU)[:WRMCI?P\^)-S?7,R1$I!;1GPHJ[VP>- M/^"7?[$7Q"$?#'P%XN^#4.K>%?@WHFK^'?AWIA\7^.+7_A'](U[5FUW5;07 M5GXDCFO_`#=4=I=]R\SKG:C*F%'GVG?\$:/^"<>FWUIJ,7[.FEW$EG,D\<&H M^,/B!J5C*T9#*EW87WBEX;J$D?-'(C(PX((J51Q4*U:I3=-^WY;J7/=.,;.U MK)J[>_D<>&X)\9,CXQXRXIX*=$M]!_#/P^\*6!W6VA>%M*M=)L1*5CC:XF MCMHU-U=M''$KRREY7"*&K>"]-O] M(\/75IXR\:^%OL6GZE=1WEW`\7A3Q#9)=AKB&-@TRR,N,*0"13EA)O#UZ?.I M5L1K*3NE?39)-V25D:XWP;XA_P"(;\=9%2SVCF?&_B'7AB,PQM6,J.';=2GS M4J4(QG*-*E1C*%)--MR=^5-)>`_L`?L]:'J'_!*SX._!+Q0L5WI/Q4^!>JW7 MB'S]+@W1Q_&`:SXHFCN;&Y7;=7-E#XGA@!E!WG34+?+P/XM[OXO?%K]GGX=? MM-_L6M/+I^G^,/BGH>E^.X(;G<\5]$]:\1:=JNGVTMMCSXK[4XM$$CJYAEM M]),9CE6<-'_H[^'-`TGPIX?T3POH-J+/1/#FD:?H>D68DEE%KINE6<5C8VWG MSNSR[+:")=SLSMMW,Q))KX4^(?\`P2U_8;^*GQ0UWXR>//@G9Z]\0O$VOP^) MMZ6GSUN6UZTW4A&K@:^%A M0KTTX1G)W<9^(_@76? M%7Q'9,)ZUO=Q:4;)>B;U:NSW^)?"7&U\?X2UN&:V'P>%\/%.A4C M5'IT91@X1E>4G!RDI6YG*[EJS^9+_`((2_'3]E[X)ZS^TS-^TMXW^ M&W@RW\1Z9\)8O!S?$1+)TU";2[KXBMKJZ3]LM)LOBKX-N_`'CN$>+?&M__;?A2_?S+K2R^I>(IFLM MS\^;;F*8=I!2P]+$T:4:#E3=)75TY7]YM[`O#OQ.X3X7P_!.*H< M/U\FITL=2EBX2Q;QW^UO$5$TW3C3O&I64=5_#3W9_.__`,$0/VZOV7OV2?A? M\M9/#WBC6VO]-L?#\MC=7`DT#1;I(0MRRKM MD96.>%_#=AK-E;WFN:WJC6D5G(R6DEM]BU*5('EN94-O\`JL/^"+/_ M``3>Z_\`#/<'_A>_$H<_^%?TKZ)^!?\`P3__`&//V;]8M?$GP>^!'@OPQXIL MDN8[+Q7/!>Z_XFLTNU9)Q9Z[XBO+NYM2T3R1[HY%;RI&B!\MF4YT\/BXT5AG M4IQII6;2DY6ZI7LNNYYF1^&?C5@N!L'X:3X@R3*>'(49X6KB\/3Q=;'/#UIS ME6C!5%3I<\U4G!2M&T>J>I_,9^VA^RWXD_9,_P"",?[.'@;QO8RZ5X_\9?M: MZ9\4/'&D3OF;1]:\5_"3XI6UEI$\6XBVN[7PSH^@6]S&"0MU!,3AB5''_&[] MDGQ9\6O^"/'[$?[1?@+16UC4?@9IWQJTSQ_9V%JDNJS_``_\4?&CQ5/;ZSB- M3+>6ND:UITCM$FX0P>([RZ8!(I&']='[1G[+OP0_:P\&:3\/_CSX,3QQX3T/ MQ/:>,=,TMM7US1!;>(K'2]8T6UU`77A_4K6:0IIFOZM%Y;R-$1=;F0NB,O7_ M``<^"_PV^`?PR\.?![X5^'8_#7P\\)PZE!H/A_[;J&J1V<.L:OJ.NZBAO-7N MY[BX$NJ:K?R'S97QYY1<(%45+!1E.2NE2=)4TNJ<9*2EM;I?>[?D=.+^CMA\ M9G>`_"?Q>^)/ASX4_''PUH>D^%O%&D^.M0MM`TOQ5?:-IEO M;'Q=X>U^YCAT^2TOQ#+-):F2&>SG66%H?(^S3W'W5:?M^?L=ZG\7?"WP,T;] MH'X=Z]\2_&4]U:>']#\/ZRNN6EY?VUO;7,6F2>(-+CETZTU2YCNXQ96TUVDU M[(DD5JDLL;HOS_\`%W_@CG_P3]^,OB#4O%6N?!*+PMX@U27SKV^^'GB3Q'X* MM)IFGFN)I_[`T?4DTL7$DD[>9)]BWD*H#`*N/0_V:TNIHI_L,%L)8SM< M$9SM#ZVG&,W"45:\KRNUZ6^)]7>U^A][P[A_&O+8Y7DN:O(L?@<`Z=.IF//B MU7KX>G:+?U5048XF<%K+VOLU)WY6?S._M!1:S_P5]_X*MWWPE\)>+;OP[\-_ M!T'B'P%X=\7V^G-KUCH/@CX9#5[WQ!XPM].MKN**9-5\72SK9S/<1"<:KIR/ M,@\J*/\`0K]HK_@C!^T5KWP5^('_``D7_!1S]H/XXP^&O"NM^+="^&/Q(E\6 MZIX2\1^)/#.DWNJ:%87B:[\6]0M]-=[V!(DNQ9S/;>>9(T8C:?VK^%/[$O[+ MGP/^*_B'XV?"7X/^&O`/Q$\5:%<>'-:U7P\=0L[*?3+W5UUR_2#05OC86-Q< M:G';O/-!;12RK:0QNYCBC5?JEU5D9&Y5E*L#CD,""#GZUE3P<6JCKOVDZS;; M3DE;3E5DTM%M==>Q\SD?@'EF+P_%F.X_G_;?$W%6,Q5:I7PV+QU"C&A42CAJ M/LH5:,)JBKM*K3J)7Y;RBM?XZ_V(/VEY_'/_``2'_;R_9M\2W\LGB#X*_#;Q M3KOA.WN7N&E/@#Q@?.FLXQ-*_E_8?%D6JAT`B14UNW5$9Q,U>_\`_!#7]LC] MEW]GO]ECQQX/^-?QP\!?#;Q-J/QFUW7;'1/%&K?8;^YT>X\+>$K.#4(X1$VZ MV:ZLKM`Q/+0,.U?MCX,_X)O?L9^`/#'Q2\)>&/@IHMEI_P`9M/UK2/B1J,VJ M^(+[Q'XATCQ!>+J&J:0?$M[J[WVF:4]VJN+:SN+>&,H/+10`!XJ/^"+/_!-X M?\V]0]N?^$^^)1Y^G_"7<5"PV(@\-*,X2G1@XOFYE>[5MDWHK)GS^4^%7BIP M[F7`>>9?F&49KF?!^4XG*7];GBXTZE&IB9SHN]*GSN5*@Z=-OF2YH]5J?8/P M6_:Z_9I_:)UG5_#WP/\`C/X'^)VMZ!IJ:SK6F^%=3-]=Z=IZ3#>Q:C':&'Q!K=U'"!=P1/NC17^7!;:<5]AUW0Y^5>T24 M^O+>WRND_P#@G]'\.RXCGE5&7%5/!TLZ^L]-&F^'OCG9Z'\=M#$5G#9VEU<^,XKBS\87=L(KB M0W,DOCS1/$\UQ,XC:6ZN9VV;=K-^)-?W!_\`!V1^SPNJ_#;]FG]J73+!!>># MO$NO?!CQ9J$45E')-HWBZU?Q7X2AO;DC[1_4_BWQ$ MRK^R>+\XH*/+2Q%3V\/\-9<[MY*3DNRM;H%%%%?HQ\2;7ASQ'KWA#Q!HOBKP MOJ^H:!XD\.:K8:WH.N:3=2V.IZ1J^EW45[I^HZ?>0,'M;R&ZABDC=2&5HP17 M^FG_`,$8/^"I'AS_`(*,?L]VUIXNU'2=*_:;^%%G9Z+\7O"5L+BW;7+..**U MT?XHZ+#.I231]699!=0PRR&PU*WGBDCAMYK!KC_,2KZ>_8]_:V^+O[$OQ[\% M_M`?!C7)M+\2^%KQ(=5TIYIET;QIX3NKBV?7_!?B>UC<"^T&^M[=`Z-EH9H8 M+N`I,:CB*:[7TJQ7\\/_`":-X]FO]>C&3D_AZCK_`/6IV.GM MTKY"_8>_;2^#_P"WI^S[X2_:`^#M_/\`V7KD,_!MM$DKW;^,/AO>VGCSP_#9"VM9II+F>]\/K:^5"ADN$ MOGMAA9VK_*/(P2#U!(/&.A].U?[0K*&!!&01@^N#UK$]8_X-OO^"5FLZOJF MKR?"7Q[82:KJ-]J3V.D_%SQQI^EV3WUS+=/::980ZELL=/C:4I#"GRQ1HJ+P MHK]Q$O%++N!L%FV6YQ0KXC"8NK"M2]A&,G&?+R5>93G"RE&-.S3>SN?D/B3 MX?X_BS&9=C\JJ4J=>A3E2J^UDX\T>92IM-1E>S<]^Y_FJT5_I,_\0UG_``2I M_P"B8?$W_P`/1X]_^65'_$-9_P`$J?\`HF'Q-_\`#T>/?_EE7Z]_Q,-P9_T` M8_\`\%4?_EY^9_\`$%N*_P#H(PG_`(,G_P#*S_-FHK_29_XAK/\`@E3_`-$P M^)O_`(>CQ[_\LJ/^(:S_`()4_P#1,/B;_P"'H\>__+*C_B8;@S_H`Q__`(*H M_P#R\/\`B"W%?_01A/\`P9/_`.5G\5/_``2J_P""F/Q-_P"";?Q_L/&.DW>I MZ]\$_&M[IFE?'#X8Q3H;3Q+X>AD>*+Q!I$-P"EGXSTJ.YN)K"X3RVE4RV4[_ M`&:XD`_T\/@E\;/AC^T5\+?!GQF^#GB[2O''P[\>:-:ZWX>U_2)Q+%+!YBBFC=%_&7_`(AK/^"5/_1+_B:?^ZT> M/?Z:E7Z*_L6_\$__`-GS]@3PWXK\&_LY1?$#1?!_C#5;?7=3\+>*OB)XE\9Z M!::Y#;K:3:QHFFZ]=RQZ)J-Q:1VT=W);",W26-N)]_D1%?Q#Q0XKX)XRJT\W MR;!XK+\\C:-5U*5-4\1!:)S<*LFJL%I&7*^:/NRVBU^K^'W#W%W"T9Y;FE:A MBLGG>4%&K)SHS>Z@G!)PD]XW5G[RW:/MJBDQZXZ>G_U_:EK\?/U,****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHR.N>/6@!"<`_Y_/%&<],>_T.<4'KG/&.G; MZU^,_P`%(_VB?VG_`-H?]N'0[K]KWXU_"SPO\#OCT/`/@?PS\/-#^#+Z9;:! M=:+_`&D(KJX\8_"[5;JYFCF&U&-QG:WS[C@CNP>!EBZ6-KNM"A2P,(SFY*3N MIU(4DDH1DV^::\K7=^AQXK%_5YX>E&C*M4Q4I1BDXKX8N3NY-):)_,_9FD&> M<_ACT_QKY*^&G[.?Q3\!^-M$\5^(_P!L?]H'XJ:-I?\`:/VSP%XWTKX(6WAC M7OMVDW^FV_\`:D#QOX$^T(WB'X6:O//#,C&3:J+<7FE3"[8,(R34,`ZRQ+PN(AB98:'M'%*<92BG:;@I1BY.FFI3 M6ZA>2NHRLGC'3=)8BA*@JTN1-N+2;7N\S3=N9W2\]'JT?HF,]\>__P!;]*,G MD\8_7OG\^'OV0O@^VM_#?P?%96NER0? MM$_$N.9'&8QXA\"/#W[0G[ M3_C+]K36[_\`;)^.GPRTKX6_M:?$KX-^$/"7@#1/@DVAV/A/PSX<\":]I@>7 MQ=\*-4O)KX3^*[V)F>Z(,=M%\H?>S[O)ZM-8CZSB:="6$A2E53YY.$JK]VG) M1@[32UFOL/W9-23BLO[2C/V7L:$ZOMY3C#6*4E!7CP"? M:E_#^7^-?E=J>O?M#_L?_M"_L]^'?&_[0'B#]HSX(?M+>.KCX02V_P`2?#/@ M[2/B'\-_B!)X9U3Q#X7UK1-9^'7AK3+77_#]]-HM]:W<%S8PFT$T'?AMI'PEN+:6\\=>%]5U M#79[^Z\=_#?6;F5S=Z;&Z!)D5?.<;2-H5_V/*RJ_7*3PLJ+KJJE4Y7&-2-*4 M.7V?.IQJ22:<;6]Y-Q:;7]HZ\GU:?MU4]FX-PNFX\Z=^9Q<7%76M[Z-)W/U( M_P`_YS17QGX/_9A^+OACQ7X=\0:O^W!^TEXVTS1M7L=1O_"'B/1_@%%H/B6T MM9UFGT;6)=!^#%E>QZ=<1JT%I>UG-QJI)>TITK).GS.3E4CTM:^NA MI4QE6G&ES862J5I\D8\T&V^64[WYK))1>[OY'ZC4F?"W@+6O#J_$GX1?&SPS\+X+#Q5X.U[Q+HNA7\WA7Q/ M\.O`FBW?A[Q1;"^WVS217\,IER\.V,QS?87Q0^`WQ*^)_B=?%OA3]K/X\_!K M1[S2=-AB\$>!-)^#.?A9JU^M]-YJF=6O#&K1XCC3D$J9?"G M2P]?Z]2EA\0YQ4TJONSI\O-"4734T[3C)-)Q:?Q732(8R)?V\OVDM'O/"GQY^ M.'PJLH-"T#]GJ.VN-$^&'Q%UOP=HVH78U'X*7#G5)[#3(9;HHR1&9V,44280 M?5?BKQU\0O!W[9'[)GP8A\;ZOJO@SQ3\#OC_`*KXUAU*UT,77C#Q%X";X3VG MA[Q#JLUEI47V748VUO6I&2R^RVS/J#Y@*I&J;5\HG1Q6(P<<73K5L+"K.?*J MB25&FZDDG*$;MJ+2MUWL9TLQ=2C2Q$\-*E2K2A&+;B]:DU!:)NUF[N_2_H?< M7.>V/US2_P"?\^E?F'X[U#XS?M0_M7?&#]GOPK\>/%7[.WPK^`7@WX>7?B&? MX6#P_#\6/B3XI^)=A=ZY'UT/XJ?%W]K/X"?%+QO;?#GX@:)\2=,T7Q#X_^#+:P+V? M1/B79>/-"TJSGU/P=#>LMOJT>JI/);V_E2PW#\)&+*%R0A/'TH8VI25949]:^-GQ!_P""A/P]_9M\%_M"?$7X M(_#[4?V4?$?QG&,=>>.:XCXE>.- M-^&/PY\>_$?6TN)](\`>#?$_C35(;01_:YM.\+Z+>ZW>06HE=5:Z>WL9%C#, M`7<`D#FOX"/V5OVUO^#@_P#;KU'QY'^RI\9/&WQ)3P$VF77BI%C_`&8_!-KH M<'B*?41HT"77Q#TW2X]0D<:;>?N[:2XEB6`-,J*Z,WT'"W!&.XIP>:YC3S+" M91E^3NDJU?&U94:2E6;4$I*$U>\;6=MU:]SY_B7C'"<-XK+<#4R_$YEC7PK_`&ZM M$_8!_P""D=B-?UWQ7XVL/AK-K>K:-X6TWQY\/?'NOVIO/";W.H^!3%H_BGP? MJ.-"N$M+6;P]XE\#6SS3W5K M96SV4\LQBC26:O9CX5<12XAH\/O$X1/$X.6/I8M5G+!U,+%7=6-6,&[7TUBK M:/9IORI>)F1K(JF=QPV)DZ.)C@ZF&=-1Q,,1+[#A*26VNDGVM?0_LH_S]:3Z M^O&!_.OXF?\`A"/^#L__`*"/C'H<_P#%P/V$./P_X2'K^M>A_P#!77_@H3^W MY^PY\&O^"?'P/TCX]:OX:_:C\6?!BX^(O[3'B!--^&&K^)Y_%.IMI.GQ>'-0 MM+/P_?:)_9%IXG;Q?86M]I>V&[_X11Y$EFC)=E2\,\9B\SRS*&.']WA%" MXK^6+_@JY_P41_;2TC_@J[\(OV+?V4?C=XL^%/A;5;7X*^`O%ECX2T#P%XKN M-1\4?$3Q/>:EKGBF"'Q+X5OIK:^M/">O:5"UL9A%C0!,47S7)^:X=X5Q_$V: M8K*\OKT82P5&O7J5:DI*DJ6'UE+F492M+[/NZW5['T6>\38/(,LPF98RA5FL M94HTH4H).HYUK6C9M*\?M:Z6=KG]?((.1W';_P#72U_(-\/?^"C'[:T?_!?O M5?V0/%7QE\07W[/=U\<_'G@[3/AA<^'_``5#IMKX:B\!:UXA\-B+5(/#D>I/ M"DEK9SQNUZSN&&]G4XKL_P#@M-_P4V_:O\.?MG?`O]@__@G]\1[SPA\4+R72 M+'XA7NA:3X:UR[U;QS\2[W3[?P1X.N!XB\-ZBNF6FGZ&1J-Y)`C2,GB*/>J" MT(F]VGX:9]5S;*,IC7PZEFN7+-%6V78WZA[&T75JXB\4HTH\UI)\U]6G9/38_K%ST!ZG\O>E_ M#^7^-?PW?MV_M]?\%2M"_P""@7AK]@;]D/\`:2\1^,/''@_P1\*?A1*]8N_&?AU+#PKJ#ZMJ]_:-;?;(+"TM/#<&6\TRR2= M6/`__!V>>/[2\8C)Z_\`"P?V$2<>P_X2*NW_`(A=BZ6"R[&YAQ3E&4+-*,<1 M1IXK%3HU949_!/DE2O:2V?RWT.)^)6&GB\;A,'PYF68RP%1T:DZ%&-2"J1MS M0YE/=-V_'8_MF_7Z?_7-(<\=,=\_TK^,?_@KY_P4,_X*'_LR_%C]B/\`9+^# M7QJ\1>'OCK?_`+,WPJO_`(WWWAS2OA]XD?XB_'#X@ZS/X.>U2VOO"-TEG>+X MA\*:G+"EDL,,T7BB`QP[5C)\I_;/\8?\'&'[`WPIL?CM\;?VL_#.L?#Q?%6D M>&+^Z\#S?"C7[C3M3U<3R:2NJ:3JGPFTR>>PN9;26(M:?:'1N95BC/F4\O\` M"O,L?A\DK2X@RS`U>(G/ZG1KUZD*M=0J.FG!*C)-3?*X._O*45N[)XWQ+P.# MK9M2CD>/Q=+(U!XJK2IPE3HN4%-J;?MT/X(0^,O!UGHLUM'K'A/Q)K5[X MH\7V_A[Q'I][;6]MJOA;P-J<$]LL4J6USXA#6YAC$:I\"?`OQU_P=`_M)?"G MPA\;?@UXR\=^*_AEX]L[S4/"7B.[UW]CGPE+J]A9:G?:1+>IH7C2?3M2M;5K MW3[KR9)[2);B()%V;5<'C,=F.6I_>`/\`'^=%?RT_"/XL_P#!7;]C_P#8=_X*"_M&?\%'O'.LZ-XT\%_# M3PUIO[-%GXBU?X!>)-)C\8^);G5]`DUF-?@R+T)K">)M3\%6]K'J;BWD>]/[ MEXUE=/R9_9A_:'_X.2OVR_AKJ?Q>_9L^)WC?XD_#W1_$FJ>$+_7HK[]DWPL\ M?B31M.TK5M1TN'1O&D&G7U])'I^M:8X>"UDCD-V(XW>1617@O#'&8VEFF+AQ M+E5'*\KKT\/+&5,3*.%JU:E*-51HU?9-3LIJ,KVM)-:V#%^(^%PDLNH2X?S" MKC\QHSKK#0HQ=>G3A4=-RJ0Y[QNXN2M>\;-VNC^_S^IX_+_]=%?RD?\`!%+_ M`(++_M&?'C]HO5/V%/VW+2RN_BQ'I_BFW\#^,[G0HO"/C.3Q?\.+/4;_`,;> M`?'>@:?:16ESK*Z/I.LWD<\5O8M`WAZ\AGCG,T'D?U;U\GQ/PSFG">:SRG-8 MP]MR0JPG2ESTJU*I?DJTIV7-"5FKV33336A]3P[Q%EW$^7+,LMO_25KXF?^(S?`+_Y74?\,8_MZ_\` M25KXF?\`B,WP"_\`E=7ZF45A_;^8_P#4/_X283_Y3Y%_ZOY?WK_^%6)_^6GY M9_\`#&/[>O\`TE:^)G_B,WP"_P#E=1_PQC^WK_TE:^)G_B,WP"_^5U?J911_ M;^8_]0__`(283_Y3Y!_J_E_>O_X58G_Y:?EG_P`,8_MZ_P#25KXF?^(S?`+_ M`.5U'_#&/[>O_25KXF?^(S?`+_Y75^IE%']OYC_U#_\`A)A/_E/D'^K^7]Z_ M_A5B?_EI^6?_``QC^WK_`-)6OB9_XC-\`O\`Y6UUO@/]DW]M3PUXW$>(O%G M_!2OXA>/_"V@^)M#UCQ'X%OOV>_@EH=EXRT/3M2MKO5?"]WK6D:>MWI-M?V, M,UJ]S;,+B!;DR0D2*I'Z/T8_QZFIGGN83C*$O8G7TK\#/V8_@!XE^,G[ M5/\`P4EU+0?VC?CK\$(M&_:?CLKG3/A'K7A?2].UV6X\/"=+_6(_$'A74'EO M8T'EQM&\:A&(*D\U^^0X.W'&,_K7\L_Q;^*/QB_9Q_:L_:O?X*?%GQ3X%M_B M3\8;_P`3^*K&VT7X=ZY:W6K6MG'96\MLWBGP/?36D2VQ*A%EP=V6R<&O>X,P M6-S#^W,'E]6G1Q57#4W&56*E!*.*H2E=.%35I.WN/7JMSES^M0P\\MKXF$IT M*=2=U!M2=ZOO+3N?O3\&?V:/%WPF\8_$5K?[5'[1GQBLVTF^TL> M$/BCK_@_4_#`FO)+61-6%MHG@VPG_M*`6[+"WG[`MS)N1B5(^(/^"DFB:C^U MWXQ\"?L1_!`6$'QHT.7_`(73XQ^+HEU*)/V>_"-GI6IZ5IL#:MX?N8;BQ\4^ M*[C4DT^*Q-S"TNERW-U)#+%Y,T/S3^R#^V#^U)XW_:"\%^'?'?QLU_QCX7N= M+^(=]J/AO5?"OPRL-/U.71/AGXRU[3$NKOPUX%L+Z**+5]+L)L07D)`-&TKX-:E\7[NYU/Q)\4/C[XO\1>/_B=XY\23VU_XAUS4CJMY MIFE:/'=P6<(L_"VF:9906VF:>BB&TB+[,O([MOC,%F/#68U,SQ]6EB5JGQ2\+^+_@)I/PLM/!NG_"KXB?LYF#X. M_%KX/63$CP)XK\.H]M'>,?'W[\2?'& MP\7_``L^+NGV,\*>'?B!X>\*Z38ZIX3O_$.F&V+7'B+3+B\F6SO$FC=(3Y$B MR190]Q^Q!X6T_P`,7?[83V$UY,?$G[:?Q5\37PO)('6*_O\`P;\,[::*T$%O M'Y=H(]/A*J_F."S9D8$!>:I76#PN8YEAZ<)0S:G0K*%:G"LH2=>I&K&U5332 MJTYNG)WER./,^;F-8TG6K8'!UI-/`SJT^:G*5/F2IQ<&G%II\LDI+;F3MI8P M_AQ^QS\4;_XO>`/CE^U-^T=J?QX\7?"1=?D^%OA;0?!'A_X:?#GPEK'B33Y] M%U3Q//H>C&6;Q!XA;1;B6WAFNIC]F$TGEY5PJ_.O_"B_$?QE_P""@_[9KZ!^ MT!\:O@>-"\&_LV"Y'PBUCPWI:^(?MW@O6S&VMC7_``QJ/G-;_9F$'E^5C[3+ MN#97;^QY['W`_`D`U_.=^VS\4_BY\!/VT_C#XC^#?Q/\1>`;SX@^%/A5%XI@ ML-&\!ZU9WP\,^&&M])>-/%G@[4)+5T2^NMWER*',O(P%`KAMYIGF8XK#8>M1 MI8EX2<*7-3A&C3BJU*;BJ<:4H13?,]*;]YWW=PS:&#R[#X:I4ISG1]NI3M*3 MJ2;@XIN;DI.VF\M$K(_6CX7_`+*7C7X=>.-$\8:K^V!^U!\3+#27NFG\$_$# MQ)X)OO">L_:;.XM$35;72?`UI<2I%).LT8CN(\2VZ%L@%3\F+\//C+X\_P"" MAW[8/_"I?V@]2^!1TSX9_LRG6SI_PU\"?$+_`(2,7.A^-A8B;_A-;27^R_LW MDW6/L^WS?MI\S/EICX;^`?[9W[7'BKXY_!SPOXE_:`\4ZUX<\0_%+P'H>O:/ M<^$/A%;0:KHVJ>*=+L=2TZ>ZTSX<07-O%/9SS1L]O/#,@D+12QN%8?L?\*_# M=C8?MJ_M8>)X9;MM0\0>`OV>[6]BE>%K2*/1](\9QVIM8U@#H["YD\S?(X)` MVA<'/5F&`S3(JV9+,:V'Q&(KX#W72IP<%%8O#:2A*C3BWOKR-[:Z*V6'KX/, MH8186G4HTJ>(7-S3?,W[&H])*&]/\`%/['GQGTK47N(H1I MGAW489[1H4N;:\TOQEX>U"TGA:X@D3<)[=,AD8%21@$Y'UEX3O;G4_"WAO4K MQQ)=ZAH&CWMU(%5`]Q=:?;SS.$0`*#+(QP!@9P.*^:QV)GB\IRR1^UW_P"KS\74?%P?\;(?V-O^R"_M8]LG M_C]^"F3QT-=O^PUX:L?"WPV^*%CI\MW-%?\`[3G[2>NS->20R2+=ZW\6O$>H MW<<9@@C`MEGG<1@@L$`#.YRQ3XD>&[&]_;E_9B\4RS7:ZAH7P=_:,T^SACDA M6SD@UFZ^%;737,;0%WE4V$/EE9$`W-N5\C;Z%6:_M[.II:2H8W\<-47ZG/"+ M_LS+H]8U&]M&BEN[&Z!;36M8; MA!;,B^0_$7QE^UQ_P3^E^&_C+XB_'>P_:G_9NUOQ]X.^&?C*U\;>#-)\+_&_ MP=)XTUJ33=+\2>&_$/AMXK7QJ$NKR,7=MJ8$K16<2VTD2O(T?BW_``52O/$7 M[$^I:C^VS^S=XMU_X?\`Q8\<-X8\*?$GP_&VDZQ\,?B59Z7?Q0:?J?B[P=K. MDS_\5#%9&*W2^T^ZL+@0PE=^Z:Y:?YL_X)T?&GXG?\%2OB]'XA_:T\5W>O>' M/V>_$GASQOX%^%G@ZTTWPA\-+_QE;6M]=Z9XC\8Z3:V4M]XIO+.]LK::UAN- M2^Q1NKJUJ\4T\,9XF*A&,*L*,N3]W^]; M=*4:T.6%G*+:<9>37QM&.-J8.G2E0S656T:E-N-)\T[Q=2/-[SY5::<'=[-7 MNOM[]HSX7ZQ\6_\`@JW\*_"^A_%CXE?!J\A_8;\7:P?%OPLU'1M+\33P6?QH MMK9]&FN-\0:-K=WX6\2^*?`,_AWQ+;Z5J-M?3Z#K]M9?#Z":?1;R.![>Z2*>*1 MH+B18Y8V(8?GK_P4Q\2^./A-^UU\,?C%\+?'6O>!/'$M5M MY?#>I_$#5-8O;:6P\5^&=1B\Y[[3K)O-5595MPJD!GW?)6A?MS_MFW6N:-;7 M/[1WBV:WN-5TZ">%O!7P75989KN&.6)FC^%ZLJLC,"58,,\$'FNNAP]GN:Y) ME&)R_%X6C@_JG(XU81=2\:E7G][ZO4=G?W??NO(SEF.783,,=1Q-&K.O[=RO M"34;.,+:>TCVU]T_37_@NC\7H_@U_P`$NOVH]7CNK:+6/&OAWP_\*=!MKB^D ML9[Z\^)/BS0_#&JC3'A(>;4+7PM>^(=16-3AH]%EW_NPU?F=_P`&TEM\-?@! M^P'\6?CG\4_'OA+X=V/Q+^,FNZC<:MXW\8^'/#VBP>"_AYHFE>'+'67FU6^A M&FQ'Q)-XPMY&F=0[:=&4&TJ7^EO^#A#P;;_%/]ECX+?#[7M9UO3_``[K7Q:M M]>U:/0WTJWNK[4-`\'ZJ=,:6?4-*N1'$CZM>L5C5-QD&3@`5_*#\,O\`@GA\ M%?&?C_PEX6U3Q/\`%]?UNRTV\FL-:\)Q7D4%S(8W>VDN/!,J),`,@O&XS MU4U]]P'PGA^(/"W&Y;5Q\\O68YD\37J4Z4:LI4<+&,(T4I5*:3V@O?AS\";6#6/% MOQ#U&ZQ-';:?DVY2*[NT@'SGJWPE\:_\%0_^"T7[2FD M_#KXO6_P3G/Q*^+?B'3?C"NH7FJV/A+PQ\)KI/!6@:QIFHZ9KVGS);ZC=VFA M0V;VUVGE-XAC*;XU.?[)/V(/^"?'[,O_``3Z_9V\7>+OV>_"5[!\1?$OPSOM M=\1?$[QG?0>)O'.K36/AR75+'3I-0^P6]MI^A1:A$LPLK*TMK>20[YDE8*5_ MAEU#]A_X4WM_>WD_B+XB&>[N+F[F*ZKX953-<3/+)M7_`(1'Y5WNV!V!K['@ MS-,/GF99[AJFYU)5<15I<_LI-RI0M#F<6D^96?* M?)<499BLLP&3XK-G3S"IQ#CZN:8JG3G4I0:4:<:=&%3E]HK*I+FE9--KEU5S M^C+X"?\`!$/]H[P1\;OA)XR\;?\`!6'6?B=X0\)_$3PAXC\3?#JS\4?$NUNO M'&BZ+KMEJ.H^%H;E_C%.()+ZVMY+<,8)E'G_`#1N,J?SI_X*BZCIW[7_`/P< M"_"KX,:EJ&CW?A#P)XP_9^^"^I0>)(_[+TB+P[H.H#XE>/=%U&Z#YN+>>[\4 M^*D28E01J,<>5501E_\`!)O]BWX0>'_^"AW[,?B)[GQ;KTWAOQ=KWB/3M.U^ M_P!#N=+_`+:T'P#XMUC0M0FALO#MO(T]GK5G87EN5F7;<6$3-N52C>'_`+<7 M[)7@/X@_MF?M5^,O$WBWXCWNM:Y^T-\8+BZE.LZ`\<,,'CS7;.PT^U^T^%Y) M(]/M=.MK2VMD:1S'!:1QEFVY)E649C2XYQM'-<]68XNCD=58>M3P.'POL)XR MM*CSJE1FHSTM91:37-8_P!#FT\;>#;^>&RL/%OAF]NYV$5O:6FNZ95B!T4$\5_"G^Q-'#^VM_P$/A%9ZC\./A1K]FD@9KN6;54^'4]S%\OFBZN7PJ#;7(?\`!+_]D#X; M^`OVS/AS\0="\0^//^$B\"^&_BGXG\/27FI>')K6WUNT^&'BZTL;V2&/PLC2 M26[WAGAPZ[9[>)SD*5/Z4?\`!O;^SGX"^'G[2?[0_P`1+*ZU_7_%VJ_#.T@? M5O$T^CWEQ:#7?&<.H:T]@^G:):M;O=7-K;&;+,KBW3Y1M!KXBGPO1\.,M\0Y M4L?+,\35RBA1A4=&-+D6.KSI5-/:U'HJ<9*2EO\`9T3/L9\15^/,QX(HUL'# M`4*68U*LX*I*HI?5J4:D-7"._-)--;/?<^'?^"@/Q7T']CW_`(.-IOVD/B)9 MR6O@CPQI/@GXF1K:0[9]9T^V_9?/A$)8Q[%%Q?W7B[2+ZTC`;$MP0C2*S,5^ MH/\`@WV_9U\:?M5_M1_M"?\`!67X^V]W?:OJ'C?QKIOPJGU%6>&[\<>-H;U? M'&N:2TT(5-(T3PCJD&@:>(`D$::K<6T*Q+8B)>6_X+^?LS^!/BY^W+H?BKQ) MJ_BZQU"'X!^`=(6'0[_1K:R-M:^*_B%/&[1W^@W,GGEKR4,1(%(5<*#DG^DS MX/?!OP9^SQ_P3@T7X4_"2*_\)Z!X3_9BU=M(U*RN84\0KK>H>`;_`%G4O%D^ MHQVJI+XGN->O+J_EN!"J?:IRR0I&%C5\2Y[2POAMPE+"494LXXCR_"Y35K:< ML,%AIRE.$+.]Z\IQ532S@FKZ(C(08S%9E"CK>>*KJ,82 MEI:U)1;CO:5GW/X3/@C\$O&W_!6+_@J/^TWKO@']H/3O@#J5YX@^+_QTT+XM M:G!J.EW]KX5TSQ]HO@WPM9:5;:/K^GSV>O3:-XKT%7,=ZA6*WNG8R$%6_H3_ M`&2_^",'[2'PB_:4^"OQ3\9?\%5=:^+WA?X>^/M$\8:O\,K37/'TLGC>W\/R MG4D\/31:K\5K^WEL)[BWA%RDMG.KVPE78"0P_F8?]AGX3R.TDGB3XC.[AI'= MM7\,EF=SEB2?"/.37ZI_\$6OV-OA;X+_`."AOP>\>Z=J_C>^UCP1HGQ(UW1; M?5=3T&?3&U"]\`>(/#+O>V]KX:ADF1+#Q!?/&%E0K,D4F2$*M^C<SEEUZ_P!1 MTW1=2N8-0T[5?!=_DP6%RQN[(`1%237F_P#P5-L?^"DO[/?Q!^&/[.O_``4F M_:/\2?'GX8^()=#^*4&D_#GXBW6H^']?T33]3N=&U.72[CQ'X(TR6R\36J_V MG#!_:6E/!%/(D\:31E9#^QW_``12_9]\&V?_``4P^,OQPU;4O$GBWXA:W\._ MC9XMN-4\3W&BW,5OXJ\:_$OP3)XA\0V,6G:%:M:ZG-!K>N6^X.5%OK%Q'L.\ M%=[_`(.*/V=?!/QC_:&^`^N^)]4\4V%WI?P=U'2;>/0;W2+6W>W'C+5[W?,F MH:'=,TWFW#C*NJ[0!MSDGR,#Q#'"<=\*<'?4*%;*\JRBE&-6>'I2Q5.M'#2J M*I0KOWZ5I*-N5Q7Q.W,TST\7D4\5PAQ'Q3]=K4\PS#,ZCE3C6G'#SINM&+A6 MI)BW MNH+>>+U3Q3+I>B:-KWBN>$(FI7^JZDGC&66[:)1)=:;<+`(X8Q$ONWP\_P"" M!_[5UCX#\'6UK_P5G_X5Q$GAG17/@#2M;\>1:=X+N)]/@N+KPQ:+H_QB@M3# M97,LUN&MX8HG\@NB*K`#SW_@M+^S_P"&/C1^U]HE[XQ\2^,U7P/\`?@WX'\- M66E7N@6MGI_A^#09O$IMPMSX;GDEE?7/$^M7#NTA^:\*J%154?D>?V%_A(,_ M\5%\1>"/^8OX9[@G_H4:]3AW+:5VES25<=D_U^DO8X?#PIXJMA%1IT*<86M0 M7O)V5DW9):*[9^_'_!9;1?$/[%?_``1@^`7[(NO?_C1XR^(_Q=L[+QE\5 M'N-1U*#XAZ7X6UGQ)\2KF2]N?$&N:C=6J1:O'X&6$+=2C=X>*AD1BA_1;_@C MWXV_9[_8@_X)&?`WQ7\9/BU\+OAW9Z[H7C;XQ^+M2UKQ!I.@ZCJ%_P"+-=UK M7K'3WTN\N4N]?\6P^$[;0=.AM;:&:[N_[*MX+6*4F)6_*+_@J9^S/X!\0_LM M?\$K?AA_:/BG1/"?PX_99LGTFRT"]T:P_M34=9\-?#8:GK>OPR:%);WFM37% ME/<23Q06Y>?5[R1@?.POYG?LT_\`!,/X!?&'XDP^$?$_BSXNV>EG3+B_:30] M?\'6EXTL%W91+&9KWP%<*(BEQ)G"!NF&&.?F)R'C6KB\'E]*O*.7X7! MX:%6M4Y:*E2I5G)RY)2GK/E>JE*UV[GTM_P2$+?M3?\`!<;XP?ML>'86\,?! MSP'XN_:C_:+\4:WXA>.TT[0?#'Q6TCXC>%?#EAKNK7)AATJX\CQY+>O+-LC2 M#P[=E]@4D?V[>`_VI_V9/BDNJ-\,OVBO@7\11H9LUUL^!/BWX`\7#1VU'[6= M.75#H'B"X^P&X%C?>1YNSS?L